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Message from the Chair

CHANGES IN HEALTH CARE

HEALTH CARE REFORM

Integrated health care delivery networks (IDNs) are operating in a new
economic reality, they still must deliver affordable care and continue to
control costs and generate proportional value.

In order to serve our patients, we must prepare ourselves and the next
generation of health care providers with not just the state-of-the-art
technology and technical skills (the goods), but equally important, we
must prepare them to be patient-centered in an integrated delivery model
(the services). This will allow the current generation to truly meet its
obligation to equip the 21st century health care ecosystem and all
stakeholders with the skills and knowledge needed to positively transform
health care, and in so doing, transform the broader American economy.

While many perceive this to be a period of uncertainty, we believe it has
the potential to present predictable and far more transparent opportunity.
Much like other industries such as the housing and mortgage industry, the
changes in the health care economy have now forced it to move towards
true market dynamics and be governed by market forces to empower the
ultimate relationship between the patient and the health care provider.

This relationship represents the common denominator between all of the
constituent stakeholders and the ultimate stakeholder—the patient.
Understanding the nexus of this relationship in a transforming data-driven
and tech-enabled direct-consumer economy will be critical. As this
transformation occurs, the health care industry will develop supply and
demand rules between providers and consumers, market forces will come
to bear, and the remainder of the ecosystem will adjust based on these
more predictable governing rules.

This will culminate in a model that is fiscally durable, while serving the
needs of the patients, especially the under-resourced and underprivileged,
and maintaining sustainability. With all the current perceived uncertainty,
the only thing that is certain is the increasing impact of charitable and
unreimbursed care and how it will be shared by the various constituents of
the ecosystem.
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AURORA HEALTH CARE’S RESPONSE
Aurora Health Care is uniquely positioned to positively disrupt the
current ecosystem and create a forward facing transformational system
that nurtures strategic partnerships across all sectors to fully capture,
extract, and transfer the value back to the patient. To perpetually innovate
market relevant goods and facilitate their delivery via equally innovative
and optimized service lines is the definition of disruptive global health
care innovation.

All of the available health care intelligence and predictive analytics
suggest that many service lines are in a phase of contraction, while
neurosciences represents double-digit growth opportunities. 		
However, the same data sources clearly articulate the barriers to such
growth being integration, technology enablement, complexity, and MDC
service models. Three short years ago, Aurora Health Care noted these
barriers and committed to developing a truly unprecedented tech-enabled
goods and services model. Aurora took the risk upon them and put the
patient-physician relationship at the epicenter, leading to the creation and
development of the Neuroscience service line and establishment of the
Aurora Neuroscience Innovation Institute (ANII).

In response to the changing healthcare marketplace, ANII recognized the
need to remove the delivery silos of care. ANII set the goal of turning the
patient into the primary stakeholder, establishing scope-constraint by
enhancing patient ownership and making sure the right team member was
providing the right care at the right time. This required breaking down
silos, removing some of the encumbrances inherent in health care. This
delivery model, in and of itself, has required as much innovation as the
robotic technology and enhancing imaging models employed.
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Everything included in the following report, be it venues of care like new
advanced robotic operating rooms or an integrated, tech-enabled,
single-reporting structure faculty, have all been built over the course of
the last three years. ANII operates under a culture of collaboration with
adjacent departments to ensure the patient remains truly the central,
primary focus and is empowered to determine their own care. Many
internationally-known physicians have joined the Aurora team since the
service line’s inception and continue to advance and progress its		
innovative and patient-centered purpose.

Like other medical disciplines, neuroscience is moving toward a 		
performance-based market demanding increased specialization, which
translates to patients often requiring multiple providers to meet their care
needs. This market environment is driving the need for highly integrated
systems of care where multi-disciplinary delivery models are required to
deliver on quality, cost, and risk-based metrics. Since the development of
ANII, we have been able to establish a care model that has incorporated
technology, many first-in-man procedures, such as Robotically Operated
Video Optical Telescopic (ROVOT-m) surgery, and have shared the work
hosting over a 100 surgeons for training to date. Our model for		
innovating and incorporating technology has been of financial		
responsibility and purpose-built development geared to measurable
outcomes and scale.

As organizations are now trying to formulate their concepts of clinical service lines, Aurora has made the successful transformation and is leading the way
nationally in integrating the neurosciences health care delivery and is embodying the principle of the patient as the primary shareholder in a		
meritocratic-based delivery system. The foundational components have been established and we are now scaling the next generation tech-enabled
integrated services model that will delivered improved outcomes at further cost reduction through iteration. We look forward to cross-institutional 		
partnerships where we collectively have to deliver care in a combined goods and services model that functions and thrives in the new realities while
staying true to the core mission:

•

Patient-centric care and the practice of clinical medicine

•

Scholarly activity for innovation and discovery

•

Educating and seeding the next generation

We welcome the new health care economy and its predictability as a path to sustainable growth. Despite our rapid growth, we have great faith in the
patient who has and will always remain as ANII’s chairman of the board.
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AURORA NEUROSCIENCE INNOVATION INSTITUTE
*Matrix Reporting

SURGICAL

Cranial

Neuro

Spine

OculoPlastics

*Ortho

MEDICAL

*Otolaryngology

Endovascular

Stroke

Inpatient

Neurology

*NeuroOncology

Neurophysiology

Ambulatory Sub-Specialties

The Neuroscience Service Line embodies integration in that many of the services and providers have matrix relationships
and dual-reporting to other departments and service lines, leading to effective collaboration for patients.
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NeuroOphthalmology

3-VERTICAL MODEL
VARIANCE

SCALE

Controlling variance within delivery system

Establishing venue-appropriate scale mapped to

to ensure stable processes, which can be

proper service locations, effectively maximizing

systematically improved upon using proper

quality outcomes and optimizing resources while

management techniques

mitigating clinical and enterprise risk

INTEGRATION
Improving inter-connections and related
processes across the system while removing

Patient
KEY SHAREHOLDER

typical care silos in delivery

BRAND
Utilizing non-traditional methods to engage
stakeholders directly through immersive digital
channels for awareness of patient care and
emerging technologies

CLINICAL

EDUCATION

DELIVER

IMAGING
Creating a DICOM hierarchical, searchable
data management system that creates
a pathway toward predictable, non-variant
care delivery

SCALE

INNOVATION
CREATE

INNOVATION
Developing the next set of commodities for
clinical care, which includes procedural
advancements as well as cellular precision
therapies and basic science research
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A Leader in Innovation
As Vice President of Neurosciences and Chairman of the Department
of Neurosurgery at Aurora Health Care, Dr. Kassam is a board-certified,
world-renowned neurosurgeon whose accomplishments have advanced
the field of neurosurgery. He was the driving force behind the
establishment of the Aurora Neuroscience Innovation Institute (ANII),
where he collaborates with an experienced team of scientists, engineers,
clinicians, and cell biologists. These neuroscience specialists work
together to provide comprehensive clinical care and emerging research
for the next wave of neurological innovation.

Shaping Tomorrow’s Care

Meet Dr. Kassam
At the Aurora Neuroscience Innovation Institute,
Dr. Amin Kassam leads a multidisciplinary team
dedicated to advancing the field of neuroscience

His neurosurgical breakthroughs have made medical history. The
innovations that have marked Dr. Kassam’s career as a neurosurgical
specialist are now helping improve the quality of life for patients with
brain cancer and other subcortical abnormalities. His most notable
accomplishments include the following:

with defining research and advanced procedures.

SKULL BASE INNOVATIONS

Aurora Neuroscience strives to provide the best

•	
The Expanded Endonasal Approach (EEA), a term he coined to
describe a minimally invasive technique that uses the nose as a
passageway to treat deep-seated tumors and lesions at the base of
the skull and under the brain. It’s also used to repair aneurysms in
major blood vessels in the brain

possible care today while defining the best care
for tomorrow.
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Dr. Kassam has been recognized globally as a defining neurosurgeon and
has contributed to profound advancements in skull base surgery and
minimally invasive approaches. During the first decade of his surgical
innovation, he was one of the key international figures in redefining
anatomical and surgical approaches to skull base surgery. During his
second decade of innovation, he has applied the same discipline to focus
on diseases of the white matter and deep subcortical spaces. This time,
not only has the focus been surgical and defining technology, but on
understanding the cellular development of underlying diseases, such as
cancers of the brain. An equally important focus has been building
service line care delivery models.

MEDICAL FIRSTS
Dr. Kassam has played a key role in making medical history by being the
neurosurgeon that successfully performed the first-in-man of several procedures
through the nose:
•	The Transpalate Approach: Dr. Kassam used this modified version of EEA
to successfully remove a large teratoma tumor from the skull base of a
newborn baby
•	Repaired a vertebral artery aneurysm through the nose using EEA
•

With ENT colleagues in Argentina, reconstructed a skull base using EEA

•

Removed an arteriovenous malformation in a child through the nose

•	Performed surgery to remove a patient’s second spinal vertebra
through the nose using the EEA approach
•	Was the first to describe the ability to transpose the pituitary gland
through the nose to remove complex tumors located behind it

DEEP SUBCORTICAL INNOVATIONS
•	The Deep Subcortical MIS Approach: Dr. Kassam developed an innovative
way to treat deep subcortical brain tumors that were once considered
inaccessible by many

ADVANCING EDUCATION
In addition to having written more than 300 peer-reviewed articles and two
textbooks, Dr. Kassam is sought after to speak all over the world about neurological
innovation—not just about what’s happening today, but also about what he
envisions for the future. He has also taught countless instructional courses and
been keynote lecturer at symposiums around the world. He encourages fellow
doctors to think critically about the kind of care they give to each patient and
to pay attention to the clinical and economic value of each new procedure.

Redefining Patient Care
At Aurora, Dr. Kassam has pioneered a patient care model
that integrates multiple specialties for complex treatment
plans – all the while prioritizing the patient’s comfort and
authority. This innovative model is geared towards
empowering the patient and removing any other agenda.
Implementing this model has allowed him to partner with
several exceptional physicians. As a patient, you can feel
comfortable knowing that all of the neurosurgical
specialists on your team are absolutely committed to
providing the best care possible. Everyone on your team
has the same goal, and that’s getting you well soon.
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Aurora Health Care
Lake Superior

Aurora Health Care is an integrated, not-for-profit, all-for-people health care
provider serving communities throughout eastern Wisconsin and northern
Illinois. Our approach keeps people in our minds and at the heart of everything
we do. We treat each person as a person, not as a patient, an illness, or
an appointment.

Lake Superior
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Our Service
Areas

Aurora got its start in 1984 when two established Milwaukee hospitals, St. Luke’s
Medical Center and Good Samaritan Medical Center, came together to form
Aurora Health Care. Over the years, our organization grew, allowing us to help
more people and communities.

Lake Michiga n

Today we serve communities throughout eastern Wisconsin and northern
Illinois with 15 hospitals, more than 150 clinics, and 70 pharmacies in 30
communities. We strive to offer services that are close to home and help make
the whole community healthier.
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Aurora Health Care is a not-for-profit health care
system serving Wisconsin and Northern Illinois with
15 hospitals, more than 150 clinics, and 30,000
employees. Aurora has been experiencing significant
growth over the past decade, and is now a fully
integrated system comprising more than 1,500
employed physicians.

Lake Michigan
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Innovative and Integrated Care Delivery Model

ANII Neuroscience Service Line

Our difference isn’t just our innovations, but our multidisciplinary teams working together to
develop a comprehensive plan specifically designed just for you. This includes a collaborative
group of caregivers committed to providing precision medicine that is adapted specifically
for your unique needs.
Your nervous system carries complex messages to and from your brain, so if this
is disrupted, you need an equally elaborate and complex team to understand and
restore these messages. Your team at Aurora can identify the source of your
symptoms, treat it with the latest procedures, and guide you on your path to an
individualized recovery.
From advanced diagnostic testing through treatment and recovery, trust Aurora
to provide you with a personalized neurological care plan. We’ll identify the best
possible remedy for your circumstances and provide the follow-up care you need
to get you back to living an active, healthy life. We treat our patients as
empowered leaders of the care team, keeping them actively involved in all
decision-making to ensure all questions and concerns are evaluated and taken
into account. When it comes to treating neuroscience conditions and disorders,
we believe the patient is the most important shareholder in the decision-making
treatment process.
Our multidisciplinary team treats a wide variety of conditions using state-of-theart technology and facilities. If you have a neurological disorder—like
Alzheimer’s, Parkinson’s, a tumor, or a condition that stems from trauma—you can
expect innovative, comprehensive medical care with a compassionate touch.
You can trust Aurora’s team of experienced neurological experts to offer the most
advanced treatment options for a variety of conditions. We combine minimally
invasive procedures and individual treatment plans with exceptional patient care
to deliver the best possible outcomes. A core commitment to providing
minimally invasive surgical options for neurological diseases and disorders makes
Aurora Neuroscience one of the most advanced and truly one of the few
completely integrated service lines of its kind.
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We continuously strive to provide the best
care available today while defining the best
possible care for tomorrow.

AT A
GLANCE
57

27

Physicians

NP/PA

$2.4M

Grant Funding

34

Research Sudies

22

Clinical
Trials

14

Research Staff

129

Research Enrollment

NEUROSCIENCE
Surgeries/Procedures

12,180

Hospital Admissions

7,636

Clinic Visits			

87,407

NEURODIAGNOSTICS

NEURO IMAGING

VEP			

52

EEG Sleep Deprived

71

CT Brain

51,382

MRI Spine			

21,564

SSEP			

13

EEG Routine		

3,551

CT Spine

12,728

Nuclear Medicine		

233

EEG Continuous 349

EEG Video			

1,828

CTA		

7,340

US Carotid Duplex

11,144

EEG Ambulatory 1,168

EMG				11,356

MRA		

3,254

Nerve Conduction

8,006

MRI Brain

19,344
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Quality & Patient Satisfaction
High quality care for your life

HOW WE DELIVER QUALITY

WHAT MAKES “HIGH QUALITY”?

We continually strive to give high quality care and results. It is a promise we
take very seriously. In order to deliver high quality, we have a step-by-step
approach that is carried out across our entire organization.

For Aurora, it’s about offering care for your life, not just for your health.
We do this by:
•

Promoting health care innovation, and staying up on the
latest advances

•

Setting high goals for ourselves

Care Management is a coordinated, patient-centered approach to finding
better ways of preventing and treating health problems. The Care
Management approach to quality means that we work together to:

•

Keeping track of our progress as we reach those goals

•

Define the health care needs of the people we serve

•

Research the best ways to meet those needs

•

Design a plan of action that can be carried out by all of our
health professionals

•

Measure our results (against national standards)

You have a right to expect high quality wherever you go for
health care. But how do you define it?
At Aurora Health Care, quality is the degree to which we give our patients
better results than they can get anywhere else.
That means we need to:
•	Update our knowledge through continuous research on “best 		
practices”—that is, how medical and nursing science prove to be 		
the best possible ways to prevent or treat specific problems
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Our main approach to delivering high quality is Care Management.

•

Set goals for ourselves based on medical science and on what 		
health care systems with the best results in the country are doing

•

Keep track of our progress and continually set higher goals

Risk-Adjusted Quality/Cost Outcomes
Our multidisciplinary approach is able to demonstrate a significant reduction on key metrics in comparison to risk-adjusted populations
across the nation. Key products chosen reflect trends in health care changes as outlined by SG2® data and analytics reporting.

						Length of Stay (Days)

Mortality Rate

Readmission Rate

Cost/Case

						Actual Expected		

Actual Expected

Actual Expected

Actual

Expected

Seizures and Epilepsy

3.39			

0.32%

0.73%		

6.99%

6.57%		

$9,030

$9,370

		3.83

Headaches and Migraines			

2.90

2.66			

0.00%

0.23%		

6.17%

8.15%		

$5,830

$7,690

Degenerative Disorders			

9.51

9.69			

0.02%

1.12%		

7.81%

10.56%

$14,383

$15,046

Multiple Sclerosis				

7.98

5.44			

0.00%

0.28%

5.19%

8.01%		

$11,269

$9,778

Peripheral/Cranial Nerve Disorders		

4.21

3.93			

0.89%

0.60%

22.28% 20.45%

$8,327

$10,777

Concussion					

2.82

2.74			

0.00%

0.53%

4.55%

4.93%

$7,138

$10,277

Cranial Surgery				3.66

5.08			

2.92% 8.68%		

8.43%

9.97%		

$19,883 $24,421

Neurotrauma					4.79

4.04			

4.72%

6.66%

7.40%

10.00%

$9,082

$11,748

Stroke (Ischemic and Hemorrhagic)

4.13

4.48			

6.47%

7.55%		

7.17%

8.82%		

$13,027

$13,737

Other Neurological Disorders		 4.52

4.31			

3.94%

3.95%		

8.17%

10.82%

$8,851

$10,398

Spine						2.96

3.01			

0.24%

0.47%

5.60%

5.98%		

$17,331

$24,895
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Patient Satisfaction
Of over 100,000 Neuroscience
admissions and visits, Aurora Neuroscience
has only 658 deaths, a rate of just 0.66%
Overall provider rating for neurosurgery,

99th percentile
Access to care rating for neurology,

NEUROSCIENCE SERVICE LINE
				Actual		

Expected

73rd percentile

LOS (Days)		 4.16			4.27
Mortality Rate

2.97			3.52

Readmission Rate

7.48			9.13

Cost/Case		$14,610		

*Data reflects medical and surgical admissions
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Office environment for neurology
and neurosurgery, 92nd percentile

$15,807

*Data reflects percentile rankings as compared to Press Ganey database

Awards and Recognitions
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BRAIN TUMORS &
NEURO-ONCOLOGY
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With 480 new primary tumors and another 1,200 cases of metastatic brain cancer expected in the state of Wisconsin every year—including
926 new deaths from the disease—Aurora Health Care has made a commitment to the early diagnosis and innovative treatment strategies of
primary and metastatic brain tumors of all kinds.
Based on American Cancer Society registry data, 7.4 people out of every 100,000 will be diagnosed with brain cancer next year in Wisconsin,
which is more than the 6.6 expected across the United States. It’s also more than the incidence expected of liver, myeloma, stomach, and
testicular cancers, as well as some forms of esophageal, Hodgkin’s lymphoma, laryngeal, oral, and thyroid cancers.
A distinctive feature of the Aurora Neuroscience program is the truly multidisciplinary approach to brain tumor management used at every
stage of treatment and diagnosis. Our specialized team of neurosurgeons, neuroradiologists, neuro-oncologists, and radiation oncologists
work collaboratively with the added expertise of medical oncology, neuropsychology, head and neck oncology, neurology, pathology, and many
others, including cancer nurse navigators, neuroscience advanced practice nurses, and physician assistants. We treat our patients as members
of the care team, keeping them actively involved in all decision-making to ensure all questions and concerns are evaluated and taken
into account. When it comes to treating neuroscience conditions and disorders, we believe the patient is the most important shareholder
in the decision-making treatment process.
Our model puts you, the patient, at the center. We see you collectively so you can ask us while we are all in the clinic room at the same
time any questions you may have. This is not only convenient, but also avoids the confusion of trying to interpret what different specialists
may have said to you at different times. We also endeavor to have the person with the right expertise in the room at the right time.
For example, we provide a neuroradiologist reviews your imaging with you as opposed to a surgeon or non-radiological specialist,
whenever possible.
Complex access and treatment algorithms have been developed to ensure that all patients, primary and metastatic, are reviewed and
considered by the Neuro-Oncology tumor conference team with comprehensive development of care plans. Through innovative
approaches to care, the management of brain tumors at Aurora Health Care has evolved beyond just length of life, and has become
fully invested in a patient’s quality of life. We offer the best of the proven current treatment available today, while bringing the next
generation of innovative chemo and surgical treatment applications to our commitment to precision medicine with innovative
techniques that adapt to the individual patient.
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AT A
GLANCE

EXPANDED ENDONASAL APPROACH (EEA)

Revolutionizing the way brain surgeons access
the skull base and upper cervical spine in a less
invasive way.
During endoscopic endonasal surgery, a neurosurgeon and an otolaryngologist
work together to enter the skull base through the nose. This minimally invasive
technique eliminates the need for external incisions and brain retraction. By
removing the back half of the nasal septum and the bone in front of the
sphenoid sinus, surgeons can reach the skull base.

2017 ESTIMATES

Brain and other nervous system
Source: American Cancer Society® Cancer Statistics Center

23,800
New cases

1,950
New cases

17,000
Deaths

979
Deaths

Brain Tumors
at Aurora

Clinic Visits

24

645
IP

507
MDC

2,591
OP

1,012
Cranial

Tumors are then removed with the help of high-definition optics and an
endoscope. Finally, the skull base is reconstructed using a flap of the septal
membrane—which seals off the brain from the nose—helping
prevent complications.
The Expanded Endonasal Approach allows access to skull base
tumors minimizing the complications that can be seen with open
skull base surgery, which include infections associated with large
scalp incisions and the side effects seen with brain retraction.
Many patients undergoing EEA spend only one to two days in the
hospital, and recovery time at home can be much shorter than for
open skull base surgery. In addition, there are many scenarios in
which EEA causes less disruption of critical nerves during skull
base surgery.
The Expanded Endonasal Approach is used to perform minimally
invasive brain surgery for these conditions:
•

Brain tumors

•

Cancers of the sinus (squamous cell, sphenoid sinus
carcinomas, adenocystic and metastatic)

•

Meningiomas of the skull base

•

Pituitary tumors (including pituitary adenomas, acromegaly,
prolactinomas, and pituitary apoplexy)

•

Olfactory neuroblastomas

Safe Access

•

Rathke’s cleft cysts

•

Skull base tumors and cysts

•

Chordomas and chondrosarcomas

We use a specialized and innovative tool that minimizes damage to
surrounding tissue by allowing neurosurgeons to safely displace the
natural folds of the brain as they advance to the target site. This is a
critical component of a minimally invasive treatment for brain tumors
and other deep-seated neurological disorders.

•

Orbital tumors and Graves’ disease

High-Definition Optics

MINIMALLY INVASIVE ROBOTIC TECHNIQUES
Deep brain tumors (subcortical), areas of bleeding, and cysts that were
once considered too risky to operate on by many are now often removed
through a precise and patient-specific corridor with our unique,
integrated surgical techniques. This minimally invasive technique
offers patients hope for better surgical results, as well as improved
long-term health outcomes. It also allows our patients to reach the goa
of zero footprint, or no long-term complications as a result of their
tumor or surgery.
Mapping
An invaluable tool for Aurora’s neurosurgeons, brain mapping depicts
aspects of a tumor and surrounding healthy tissue with enhanced
clarity rendered in a three-dimensional space. This imaging technology
allows surgeons to preplan a patient-specific, real-time surgical pathway
before a brain surgery procedure even begins—which translates into
improved outcomes in the operating room and a faster recovery.
Dynamic Navigation
Neurosurgeons use a GPS-like system that gives them real-time guidance
deep within the brain. Patients can see their brain tumor removal on the
same computer screen that their surgeons use to track the movements of
their surgical instruments.

This technology allows neurosurgeons to differentiate tissue types with
unprecedented clarity from above the surgical site. Being able to
separate diseased tissue from healthy tissue makes it possible to
successfully remove what would otherwise be considered inaccessible
brain tumors, cysts or other growths difficult to see.
Automated Resection
Using a tool about the size of a pencil, neurosurgeons are able to remove
tissue without injury to adjacent healthy brain matter. This technique is
another reason Aurora can offer treatment options for conditions,
such as brain tumors, that were previously deemed too risky by many.
Directed Therapy Options
Neurosurgeons collect and preserve the brain tissue they remove in
a sterile, closed-capture device for pathology, molecular, and genetic
evaluation. These samples provide opportunities to develop personalized
treatment regimens for every patient. This is a critical step in advancing
treatment paradigms. The ability to capture, grow, and implant the tumor
tissue into mice enables the team to study and develop new targets for
treatment that are brought directly back to the patient in
an individualized manner, epitomizing our commitment to
precision medicine.
All of this patient and correlated cell data is then compiled into a novel
image-driven data capture system with the goal of developing predicted
informatics power. Aurora was the first institution in the world to install
and implement this specific image-driven informatics system.
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The culmination of all of these integrated
technologies allows for many of our patients to
have surgery while awake. However, this is
different than the way awake procedures have
been commonly done in the past. Our patients
often have less anesthesia than even routine,
non-neurosurgical procedures, like a colonoscopy.
Also, many patients are interacting on their
phones or smart devices during surgery, and
many, go home the next morning.
We believe this has resulted in significant
improvements in cognitive outcomes, particularly
those that are otherwise difficult to monitor when
patients are completely asleep during surgery. This
philosophy of care has been paramount to our
continued pursuit of zero footprint, or no
long-term complications.

26

BRAIN MAPPING

Advanced brain mapping technology lets our
team of experts see the precise location of
individual brain functions—speech, memory,
and movement—in order to help determine
the most appropriate treatment.

Brain mapping is a fundamental element of our minimally invasive
methodology for treating subcortical tumors and cysts that were often
considered otherwise inaccessible.

Brain mapping is a critical tool used by neuroscientists to diagnose
long-term, chronic conditions, like Parkinson’s disease; it is also used
to plan surgeries for more acute conditions, such as brain tumors.
If surgery is needed, brain imaging technology may be used before and
during a procedure to differentiate healthy brain matter from diseased
tissue. It can also be used to define a surgical or navigational strategy
to help avoid injury to portions of the brain needed for critical functions.
Diffusion tensor imaging with white matter tractography is one type of
brain mapping. It uses state-of-the-art technology to create a 3D map
of the brain, which shows the location of nerve fibers that control speech,
memory, cognition and thought—all of the things that make you … you!
It provides advanced assistance with:
•

Determining the best surgical approach to remove a tumor

•

Diagnosing and treating a traumatic brain injury

•

Finding breaks in brain fibers that may cause the loss of certain 		
body/memory functions

•

Understanding which brain connections are intact and
which are damaged

•
Other types of brain imaging technology that works like a GPS 		
	system during surgery, giving neurosurgeons real-time guidance 		
deep within the brain

Aurora has performed more optical robotic
brain surgery than anyone in the world to
date, and ANII was the first in the world to
deploy a unique 3-D brain mapping
platform for patient care.
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Neuroradiologist
•	
Uses advanced technology to diagnose diseases of the nervous system
Surgeons
•	
You will see one of our world-renowned neurosurgeons who will perform
any necessary procedures

•

Communicates regularly with other providers on your care team

Financial Advocate
• Answers questions about insurance coverage
• Discusses any payment or financial concerns and options
Primary Care Physician
• Views your progress via your health record
• Sees you during the full recovery process
Care Coordinator
• Your most regular point of contact
• Assists with scheduling appointments
• Stays in touch with NP, PA, and surgeon
• Ensures you’re comfortable and taking medications
Cancer Nurse Navigator
• Makes sure you receive seamless care
• Schedules appointments with specialists
• Connects you with support groups

The MDC team approach is
progressive and is different from
most multidisciplinary teams that
exist today in that it functions as
one fluid unit instead of operating
in specialty silos.

Nurse Practitioner (NP) and Physician Assistant (PA)
• Specially trained advanced practice providers
• Performs daily physical exams, reviews tests, and medications
• Follows you in the hospital and clinic
• Will assist your surgeon during surgery
Other Specialists
Communicate and collaborate with other care team members, including the following:

•
•
•
•
•
•
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General neurologist
Neuro-oncologist
Rehab specialist
Endocrinologist
Otolaryngologist/ENT
Medical Oncologist

•
•
•
•
•

Spine physiatrist
Neuroendovascular specialist
Neuropsychologist
Neuro-ophthalmologist
Radiation oncologist

Brain Tumor Distribution

%

56.4%

60

Other Malignant
Tumors

Other Benign
Tumors

3.8%

Metastases

5.4%

Unspecified
Tumors

2.6%

Glioblastoma

3.5%

Meningiomas

19.6%

0

.48%

8.2%
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Cavernous
Tumors

Neurilemmoma
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COLLABORATION
TAKES FLIGHT
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Not everyone would
compare a successful
multidisciplinary
neurosciences center to
the airline industry.

However, not everyone is world-renowned
neurosurgeon Amin Kassam, MD, who sees
parallels between commercial flight and a
health care model built on value through risk
reduction rather than volume.
“I wanted to build a health care service line that mitigates risk, and the airline industry
has done that well,” he says. “Flying is a safe event, when you look at the number of
flights as opposed to the number of plane crashes. You can look at health care the
same way.”
With that in mind, Kassam spearheaded the creation of the Aurora Neurosciences
Innovation Institute (ANII), a multidisciplinary program of the Aurora Health Care
Medical Group in Milwaukee, Wis. The program’s goal is to create a collaborative
environment where neurosurgeons pilot through brain surgery with navigation from
neuroradiologists—all working side-by-side in the OR. Each team member provides
support for the competency for which they are best suited.
Typically, imaging would be done in a separate location and provided to neurosurgeons in preparation for surgery. By combining efforts in one location, Kassam says
patients benefit from more immediate care.
According to Jonathan E. Jennings, MD, section chief of neuroradiology for Aurora
Health Care Medical Group and a neuroradiologist with ANII, the overarching goal of
the new program is improved outcomes, decreased patient morbidity, and reduced
length of stay for patients. “In the two years since the program began, we’ve amassed
a significant amount of data about the progress of this multidisciplinary approach,”
he says. “Now we’re analyzing that information to help us drive better		
patient outcomes.”

MODEL DESIGN
In 2014, Kassam was recruited by Aurora Health Care Medical Group to build its
multidisciplinary neurosciences program. Kassam has had extensive experience over
the past two decades in building service lines focused on multidisciplinary
collaboration and proposed the concept of integrating neuroradiology as a clinical
component of neurosciences. He designed the ORs and clinics to contain reading
spaces for radiology. This meant actually seeing patients in the clinic, in the operating
room, and in postoperative acute and outpatient venues.
Radiologist Dale J. Lye, MD, who leads Aurora Imaging Services, was also		

forward-thinking and supportive of establishing the ANII, not only
because it provides a higher quality of patient care but because
it is a natural progression in the evolution of how radiology will
need to look in the future, particularly as health care moves from
volume to value. This open-minded thinking led to a natural
collaboration that broke down silos and made implementing the
concept much easier.
During the design process, the imaging team analyzed the
clinicians’ workflow to see where having a radiologist on site
could help improve efficiency. They realized neurosurgeons were
spending time weeding through stacks of imaging reports in
order to plan their next course of action. In response, they
proposed that adding a neuroradiologist to the crew would provide the guidance necessary to complete a surgical flight plan.

“At ANII, neurosurgeons are pilots, radiologists are
the navigators, and the OR is the cockpit,” Jennings says.
PLANNING AND WORKFLOW
The cockpit of this multidisciplinary clinic space comprises a
state-of-the-art, four-room operating theater, with a dedicated
planning room embedded within the semi-restricted area
adjacent to the OR. Neuroradiologists work together with their
neurosurgery colleagues within that space.
The need for efficiency in radiology is maintained on the OR floor.
At ANII, reading rooms are located within the OR suite and allow
neuroradiologists to read nonsurgical cases during down time. In
addition, a network of video communication creates connectivity
between the OR, the planning room, clinical offices, and the main
radiology reading room–essentially creating air traffic control.
With this model, no one service line “owns” the patient. “Just as

a plane doesn’t have just one pilot, a patient doesn’t
have just one surgeon taking care of him or her,” Kassam
says. “There are always two attending doctors with a patient, and
we put the radiologist in the cockpit with us, reading images and
providing our navigation in real time. In fact, the radiologist
generates the flight plan before we even see the patient.”
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Neuroradiologists also play a direct role with
patients within the clinic setting, joining oncologists
in discussions with patients about the benefits and
risks of surgery. For most complicated discussions, the 		

participates in planning and workflow. We are included in the overall work
environment. Within this model, having a neuroradiologist immediately
available at critical moments during anatomically complex procedures can
decrease the potential for adverse outcomes.”

neuroradiologist reviews the imaging directly with the patient and the rest
of the team. Patients have the opportunity to ask questions while all the
members of their treatment team are in one place. It’s a unique role for
radiologists, who historically don’t have much patient contact.

According to Fukui, radiologists are involved with the pre-surgical planning

Each member of the team brings a different strength to the case at hand,
Kassam adds. “A surgeon can put information about a patient’s case into
the context of the disease, but a radiologist has the data and the ability to
present the information at clinic in a way that the patient can understand,”
he explains.
“With this program, we break down the silos and form a collaborative unit,”
Jennings says. “As the silos break down between medical specialties
everyone comes up with good ideas. We are fortunate to have been
welcomed as integral members of the neurosurgical care team.”

THE PATIENT CARE CONTINUUM
Melanie Brown Fukui, MD, a neuroradiologist at ANII, embraces the opportunity to work side-by-side with neurosurgeons. In addition to providing her
imaging expertise in the OR, she is in a position to bridge patients’ imaging
needs from their clinic visit through preoperative planning and into the
operative and postoperative phases of their treatment.
“This is a window into neuroscience here that I believe doesn’t exist
anywhere else,” she says. “We’re a multidisciplinary unit in which radiology
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along with the surgeons. They also stay in the OR during “inflight cross

checks” when the surgeon is working in the brain, following the anatomy
in imaging.
“We have come to speak a common language with our partnering
neurosurgeons and advanced practice providers,” Jennings says. 		
“We directly observe the manner in which imaging is used for operative
guidance, and have accordingly designed a set of pathology-specific MR
protocols to fit the unique operative approaches and technologies our
neurosurgeons use.”

COLLABORATIVE IMPACT
Jennings, Fukui, and Kassam agree that the collaboration among members
of the ANII team strengthens the clinical environment and incrementally
improves patient care.
In one instance, during surgery to remove a cluster of blood vessels from
the brain of a 36-year-old man who suffered from seizures, imaging
guidance in the OR suite provided Kassam with a map to the malformation.
It also helped that the patient was kept awake during surgery in order to
regulate the effects of the surgery on his functionality.

The culmination of this collaborative process has yielded significant results in a short
period of time. The neurosurgical oncology service has posted a 30 to 40 percent
reduction in length of stay, mortality, and readmission rates as compared to national
risk adjusted rates. This has also translated into a financial benefit, with a 10 percent
reduction in cost per case, despite increasing the case complexity in comparison to the
pre-ANII era.
The neuroradiologists also benefit from direct and immediate clinical-radiologic
correlation, observing surgical procedures in real-time and working in sync with		
surgeons and other members of the team. This enables imagers to see how their 		
navigation helps the surgeon, and where they can improve the process of providing
the right map for surgeons to follow.
Jennings points out that participating physicians share information and learn from
each other. “Now, the radiologist is involved at the point-of-care,” he says. “We interact
with each other in a more natural way, with amore open flow of communication.”

NEXT STEPS
•	Look for opportunities across the health care continuum where the
radiologist can come into more direct patient contact.

KEY
TAKE-AWAYS
1 A team of neuro-oncology
specialists breaks down silos and
provides patients with a multifaceted
approach to neurological issues.

2 Neuroradiologists join the clinical side
of medicine by providing real-time image
guidance within the OR and playing a
direct role with patients in the clinic

•	Seek out the clinicians in your practice or facility who use and value
imaging the most, and work to form alliances between them and your radiologists.

•	Develop collaborative models that overcome silos in budgeting by
valuing risk reduction for the patient rather than volume delivery by the provider.

setting.

3 The neurosurgical oncology service has
posted a 30 to 40 % reduction
in length of stay, mortality, and readmission rates, as well as a 10% reduction

in cost per case.
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SURGICAL INNOVATION
Recent innovation in the field of neuroscience has created dramatic
advancements in neurosurgery through the engagement and collaboration of
several unrelated disciplines joining forces, particularly the safety principles
of the aeronautics industry. Neuroscience is now realizing this same value of
integration and unification based on diverse stakeholders like health care
providers, technology, and even our patients.
Aurora’s neurosurgical operating room of the future is a space in which one of
its mains goals is to gather information in the OR in real time in order to serve
patients and surgeons on a global scale. At Aurora, we’ve adopted the theory
that the state of information overload can be resolved by a simple
understanding of the power of visualization and collection of data in real time.
The foundational architecture of aerospace industry and innovation
continues to provide guidance for the operating room of the future. Aviation
safety experts measure air traffic routes for safety using quality metrics. Our
new software allows us to map millions of previously unseen white matter
tracts in real time, rendering them in a three-dimensional modeling system.
Like air traffic routes, we are now able to apply principles of aviation safety to
the white matter tracts of the brain.
ANII has been an international leader in this effort, recently presenting a
unique three-dimensional patient-specific atlas of the human brain. This
means that each patient can have their individual case planned and simulated
just like a flight plan–this is a critical step towards precision medicine.
The planning of each surgical case begins with precise, detailed, and
advanced imaging. The complex imaging data is thoroughly evaluated by a
computer algorithm that determines whether or not it is ideally suited for
surgical planning. Once the surgical plan is generated, it is transferred directly
to a robotically-operated video optical telescopic microscope (ROVOT-m)
with a built-in navigation system. Aurora and the team at ANII were the first
in the world to deploy this integrated system for direct patient care.
This system represents a single, integrated intraoperative solution to allow
surgeons to accurately reach their target while protecting sensitive brain
matter. The plan is displayed onto a high-definition monitor and merged with
imaging confirming alignment for a precise trajectory in order to develop an
individualized corridor of entry for each patient.
The ANII care delivery model is equally unique and innovative as the
technology. The system is designed so the neuro radiologists (navigators)
design the flight plans in the OR (on the runways) and are actually present
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during the critical portion of the procedure to provide input when needed. In
addition, every effort is made to ensure that two experienced surgeons (pilot
& co-pilot) are performing the key portions of the procedure together,
whenever possible. Very few commercial flights operate with just one pilot
to avoid errors and maximize quality assurance; we are committed to patient
safety in the same manner. This has led to creating innovative models that
overcome financial barriers.
Aurora neurosurgeons are now able to see the “flight plan” on this imaging
platform to prepare themselves to navigate the complex anatomy of each
individual patient in advance. They are able to take off and fly through the
surgical space with autopilot functionality as well as have the freedom to
adjust the plan while in flight if obstacles arise and if deviation is necessary.
Information is being acquired in an intelligent, user-friendly manner with		
ability to record, capture, and share in real time, giving rise to an 		
iterative loop.

PROCEDURES

Integrated

Safety
SYSTEM

Quality
Assessment

Flight
Execution

In-flight
Radar

Flight
Data

Planning
Software

Robotically
Operated
Video Optical
Telescope

Advanced
Imaging

Value
Judgment

Navigation

Robotics

Optical
Platform

Black Box Information >> Predictive Informatics
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MOVEMENT
DISORDERS
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Parkinson’s disease may be part of your life,
but it shouldn’t define it.
Eating breakfast. Writing your grocery list. Walking to the car. Driving
to the store. Most of us do these activities without a second thought.
But for a person with a movement disorder like Parkinson’s disease,
these simple things can be challenging—or even dangerous.
Parkinson’s disease is a brain disorder that leads to shaking (tremors)
and difficulty with walking, movement, and coordination. While there
is no cure, treatments can reduce the symptoms and improve your
quality of life. Diagnosing Parkinson’s disease can be difficult,
particularly in the early stages of the disease. Our team uses
neurological exams, SPECT scans, and MRI to assist in diagnosis.
We also offer DaTscan to help confirm a diagnosis, which is an
imaging technology that uses small amounts of a radioactive
drug to help determine health of the dopamine system in a person’s
brain. A SPECT (single photon emission computed tomography)
scanner measures the amount and location of the drug in the brain.

BY THE
NUMBERS
ER/ Urgent		

Parkinson’s

1.94%

Inpatient		 88%
Outpatient Visits

851

ER/ Urgent		

43.8%

Tremor Inpatient		 N/A

Huntington’s
and other choreas

Outpatient Visits

310

ER/ Urgent		

0.28%

Inpatient		 2%
Outpatient Visits

11

ER/ Urgent		

4.17%

Dystonia Inpatient		 N/A

Ataxias

Other Movement
Disorders

Outpatient Visits
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ER/ Urgent		

8.06%

Inpatient		 N/A
Outpatient Visits

2437

ER/ Urgent		

41.81%

Inpatient		 10%
Outpatient Visits

271
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“You all made a difficult time easier for me. I came
away with a better attitude and more hope.”
- Jerry D., Big and Loud program participant
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EASY STREET
Easy Street is a one-of-a-kind therapy environment and facility that provides
a variety of real-world experiences to aid in the recovery of our patients,
specifically those suffering from neurological and movement disorders. This
facility includes a grocery store, barber shop, movie theater, bus, driving
range, and apartments so our patients have a unique opportunity to be
challenged both mentally and physically over curbs, ramps, and uneven
surfaces before they face those obstacles in the communities we serve. Easy
Street allows for a truly multidisciplinary approach to care by creating an
environment where physician, therapist, and other medical professionals
come together to focus on one priority, helping your patient regain their
highest functional level and re-enter the community.

Mobile and Fit Parkinson’s Class
This exercise class is designed so that people with Parkinson’s disease can
get better and stay better through exercise. The class targets movement
deficits caused by Parkinson’s disease with the goal of reducing falls,
improving function, and improving quality of life.
Health Counseling
Many patients experience anxiety and depression after their diagnosis.
Specialized therapy sessions can help them learn to cope with the
emotional changes.

FUNCTIONAL NEUROSURGERY LAUNCH
PARKINSON’S SUPPORT
LSVT Big and Loud Clinic®
For People Living with Parkinson’s Disease
•

Evidence-based exercise program that follows an intensive
and specific protocol to provide maximal results

•

Specialized treatment from certified therapists for Parkinson’s disease

•

This treatment has been linked with better outcomes compared to
traditional therapy

•

Patients learn how to move BIG and speak LOUD on a consistent basis

•

Recalibrates the senses for automatic use of normal movement and voice

•

Uses high effort and intensive treatment to improve everyday function

Aurora Health Care recently saw the launch of its functional neurosurgery
program with capabilities in both epilepsy and movement disorders surgery
led by a specialist from one of the best functional training programs in the
country. Our program focuses to not only surgically treat epilepsy and
movement disorder patients (Parkinson’s disease, essential tremor, dystonia,
etc.) who have exhausted other options, but also do it in a manner that has
the highest level of safety with the least invasive approach, including laser
ablation for epilepsy and asleep deep brain stimulator (DBS) placement.
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NEUROLOGICAL
DISORDERS
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Our neurology team is part of a family of services that includes the
latest diagnostic technology and proven physical rehabilitation services.
Our neurologists lead and participate in clinical trials to bring our
patients the next generation of treatments.
Chronic headaches. Degenerative neurological disorders. Persistent
muscle pain. At Aurora, we understand that medical issues like these
require experienced, compassionate care. Our multidisciplinary team
will identify the source of your neurological condition with state-of-theart diagnostic services and provide treatment tailored to your needs
and goals.
Neurologists at Aurora Health Care will partner with you to create a
treatment plan for your brain injury or disorder. Our neurologists will
help you deal with existing symptoms, treat your symptoms, and
monitor your health to ensure you enjoy the best quality of life possible.
Our team works to diagnosis and treat the following
neurological disorders:

AT A
GLANCE
Average rate for readmissions to the

,

hospital was 7.5% however

• Alzheimer’s disease and other cognitive disorders

expected return was 9.2% showing

• Epilepsy and seizures

the advanced treatment of Aurora’s

• Multiple sclerosis
• Parkinson’s disease and movement disorders

neurology care leading to longer term
outcomes and improvement.

• Stroke
• Headaches and migraines
• Neuromuscular disorders
• Neurodegenerative diseases
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Neurological Disorders

IP Admissions

OP Visits

10,000
8,000

Seizures &
Epilepsy

42

Headaches &
Migraines

Peripheral
Nerve
Disorders

Concussion

Alzheimer’s
and Cognitive
Disorders

510

32

365

65

644

24

6,883

1,938

Stroke/
TIA

11,341
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Multiple
Sclerosis

36

0

2,820

4,542

191

2,000

773

4,000

1,328

6,000

Hydrocephalus

CONCUSSION
According to the Centers for Disease Control (CDC), an estimated 300,000 people under the age of 19 were treated in hospital emergency rooms for
concussions related to sports and recreation activities alone last year. This number is doubled over reports 10 years prior, due in large part to the increased focus
on the identification of and need for immediate treatment for concussion. This is good news, considering 90% of most diagnosed concussions do not involve a
loss of consciousness (LOC). Prior to recent awareness, this lack of LOC led many parents and coaches to brush off any substantial hits or collisions as requiring
medical attention.
Research presented to the American Academy of Pediatrics’ annual meeting concluded that school and sports teams with athletic trainers on site have higher
rates of concussion than those that don’t due to their expertise in identifying the injury and its oft-subtle signs immediately.
Aurora takes concussion care seriously and has been a proven leader in concussion assessment, treatment, education and prevention. Aurora is the top employer
of athletic trainers in the state of Wisconsin. By providing these front-line prevention resources, Aurora’s athletic trainers ensure baseline tests are administered
properly, contact techniques are being safely instructed, and student athletes and parents are appropriately educated to assure that all safeguard elements are
in place for all high-risk activities.

ER

Neurological Disorders

Urgent Care

10,000
8,000

Seizures &
Epilepsy

Headaches &
Migraines

Peripheral
Nerve
Disorders

Concussion

Alzheimer’s
and Cognitive
Disorders

3

17

171

21

352

0

1,422

577

1,087

12,496

8,922

2,000

93

4,000

2,065

6,000

Hydrocephalus

In the event of a head injury, athletic trainers have certification and state licensure that assures evidence-based practice of proper concussion management.
Over 70 Aurora athletic trainers across the state provide on-field assessment using researched protocols and follow the National Athletic Trainers Association
position statement on management of sport concussion.
Aurora’s athletic trainers work with a complete team of dedicated health professionals, including pediatricians, orthopedic surgeons, neuropsychologists,
neurologists, family practice physicians, and physical therapists to reassure proper return to play.
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AT A
GLANCE

Aurora performs nearly 7,000 baseline
concussion tests to student athletes
throughout the state of WI annually.
There are between an estimated 1.6
and 3.8 million sports-related
concussions in the U.S. every year,
leading the CDC to conclude that
sportsconcussions have reached
an epidemic level.
The CDC reports that of college
football players, 34% have reported

experiencing concussion, and as many as

20% have experienced more than one.
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DATA

MULTIPLE SCLEROSIS
Comprehensive care clinic associated with the National MS Society
Multiple Sclerosis (MS) affects women more than men and most commonly begins between the ages of 20 and 40. Doctors aren’t sure
what causes multiple sclerosis, but it is an immune-mediated illness.
Genetic factors and exposure to certain viruses are thought to be involved in the development of multiple sclerosis. No two people have
the exact same effects, which can make diagnosing MS difficult at times.
Aurora’s expert neurologists work with patients to determine the best way to slow or stop the destruction of the nerves’ protective coating.
The right treatment can significantly reduce symptoms and prevent them from becoming disabling. We’ll help you cope by giving you
access to the latest in MS research and treatment options.
Collaboration with:
• Neurology
• Neuropsychology
• Occupational Therapy

National standards show a 0.28% rate of
mortality for those suffering from MS; in
2016, Aurora’s mortality rate was 0.00%.

• Physical Therapy

Return trips to the hospital occurred at a

• Speech and Language Pathology

rate of 5.19%, while risk-adjusted

We believe in comprehensive care that treats the
whole patient, including your spiritual, physical, and
emotional medical needs. In addition,
we can help you manage symptoms like
cognitive deficits, swallowing and speech issues,
bladder or bowel difficulties, spasticity, fatigue,
depression, stress, tremors, and weakness.

expectations were much higher at 8.01%.
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599

EMU
Admissions
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EPILEPSY
According to the Epilepsy Foundation, epilepsy is the 4th most common neurological condition. Every year,
48 new people of every 100,000 will be diagnosed with epilepsy, which means that 1 in every 26 people will
develop epilepsy sometime throughout their life. Current statistics show that in the United States, there are
roughly 2.2 million people diagnosed with and being treated for epilepsy and seizures.
At Aurora, a seizure evaluation consists of a detailed discussion of your symptoms, a comprehensive neurologic
examination and diagnostic testing. Basic testing includes an EEG, or brainwave test, to see if we can capture a
seizure or see footprints of seizure activity. We may also get an MRI of your brain to see if there is an abnormality
or malformation that can cause seizures. Our expert neurologists can help you manage these debilitating occurrences—
regardless of their source—so you can lead an independent, productive life. We’ll start by determining whether you have
generalized-onset or partial-onset seizures and then develop a seizure treatment and management plan that’s right for you.

EPILEPSY MONITORING UNIT

ABRET LAB ACCREDITATION

Patients whose seizures can’t be controlled with medications and those who
may be candidates for epilepsy surgery are often scheduled for long-term
epilepsy monitoring in one of our Epilepsy Monitoring Units. Information
from the study is used to determine if surgery is a viable treatment or if
other options should be considered. This information helps to do
the following:

The Laboratory Accreditation Board of ABRET has granted the EEG
Laboratory at Aurora St. Luke’s Medical Center a five-year accreditation.
This award is based on an evaluation of the technical quality of the EEGs
performed in this lab and on a review of specific policies from the Policy and
Procedure Manual. The lab has been commended on their desire to promote
excellence and competency in the department which has had a positive
influence. There are only 156 accredited labs in the country.

•

Establish an epilepsy diagnosis. In most epilepsy centers, about 1 in 4
patients who have seizure-like events do not have epilepsy

•

Identify the seizure type. Some seizure medications are designed to treat
certain types of seizures

•

Locate the source. Monitoring can help identify the brain area where
your seizures begin. Lateralization and localization (finding the side and
area) of your seizures is a critical first step in planning any epilepsy
surgery. Seizures are videotaped because your behavior during seizures
can also help to locate the source

•

EEG
TESTING

Determine seizure frequency. Video EEG monitoring can identify how
often you are having seizures. Frequently patients have seizures and
don’t know unless someone tells them
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In 2016, Aurora saw over 20,000 visits to the emergency
department or urgent cares for headaches and migraine.
NEUROMUSCULAR

Dysautonomia Center

Dysautonomia

The Dysautonomia Center at Aurora Health Care is one of only two centers
in Wisconsin offering specialized diagnostic testing and treatment for people
with complex ANS disorders. Our multidisciplinary team approach includes
medical experts in neurology, cardiac electro-physiology, psychology,
gastroenterology, rehabilitation, nutrition, integrative medicine, genetics and
more. Our team focuses on identifying the root causes of dysautonomia and
participates in clinical trials to determine the most effective treatments and
improve the quality of life for patients with this condition.

Dysautonomia occurs when there’s a malfunction in the autonomic nervous
system (ANS), potentially affecting heart rate, blood pressure, digestion,
sweating and other automatic processes in the body. Doctors can’t always
pinpoint what causes dysautonomia. It may be secondary to a multitude of
other medical conditions, such as diabetes, multiple sclerosis, rheumatoid
arthritis, celiac disease, Sjögren’s syndrome, lupus, Parkinson’s disease and
many others. Sometimes it develops after a trauma or a virus. It may also
happen to adolescents after a growth spurt. Dysautonomia can be a mild and
temporary condition or a serious long-term illness.
Dysautonomia is not rare. Recent National Institute of Neurological Disorders
and Stroke data reports that over 70 million people worldwide have been
diagnosed with varying forms of dysautonomia and confirms that it affects any
age, gender or race. Although there usually is no cure, advanced treatments
are being used every day to help patients better combat the dysfunction of
their ANS. The largest issue that physicians face is the difficulty associated
with actually diagnosing the condition, as it can mask itself as a number of
other neurological disorders.

Over 1 million Americans are
impacted with a primary autonomic
nervous system disorder.
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Autonomic Function Testing
There are number of tests that can help to diagnose and quantify the
severity of autonomic dysfunctions. Some tests use deep breathing
techniques to quantify heart rate and blood pressure responses to evaluate
the function of autonomic nerves. A tilt table test can quantify blood pressure
and heart rate responses to the stimulus of moving a person from a supine
to an upright position. An advanced form of diagnosis for dysautonomia is
testing of sweat function. This can be done by the quantitative sudomotor
axon reflex test (QSART) that quantifies the sweat that occurs by activation of
small nerves controlling sweat glands in the skin on select confined areas on
the limbs. This test evaluates the peripheral component of the ANS controlling
sweat function. The thermoregulatory sweat test, where patients are covered
in a reactive powder that turns color when the body sweats, assesses both
the central and peripheral ANS. This test shows the pattern of sweat a patient
experiences, helping physicians diagnosis a number of different autonomic
disorders. These two tests of sweat function in combination can help doctors
localize and more precisely diagnose the type of autonomic dysfunction. The
Dysautonomia Center Autonomic Laboratory is specifically designed to
evaluate, quantify the severity of, and help lead to the treatment of
ANS disorders.

HEADACHES AND MIGRAINES
Headache is our most common form of pain and a major reason cited for days
missed at work or school as well as visits to the doctor. The International
Classification of Headache Disorders, published by the International
Headache Society, is used to classify more than 150 types of primary and
secondary headache disorders. Primary headaches occur independently
and are not caused by another medical condition. Migraine, cluster, and
tension-type headache are the more familiar types of primary headache.

non-invasive vagus nerve stimulation (which uses a hand-held device to
transmit a mild electrical stimulation to the vagus nerve through the skin), and
oxygen therapy (in which pure oxygen is breathed through a mask to reduce
blood flow to the brain). Certain antipsychotic drugs, calcium-channel
blockers, and anticonvulsants can reduce pain severity and frequency of
cluster headache attacks.
Prognosis

Secondary headaches are symptoms of another health disorder that causes
pain-sensitive nerve endings to be pressed on or pulled or pushed out of place.
They may result from underlying conditions including fever, infection
medication overuse, stress or emotional conflict, high blood pressure,
psychiatric disorders, head injury or trauma, stroke, tumors, and nerve
disorders (particularly trigeminal neuralgia, a chronic pain condition that
typically affects a major nerve on one side of the jaw or cheek).

Not all headaches require medical attention. But some types of headache
are signals of more serious disorders and call for prompt medical care. These
include: sudden, severe headache or sudden headache associated with a
stiff neck; headaches associated with fever, convulsions, or accompanied by
confusion or loss of consciousness; headaches following a blow to the head,
or associated with pain in the eye or ear; persistent headache in a person who
was previously headache free; and recurring headache in children. Migraine
headaches may last a day or more and can strike as often as several times a
week or as rarely as once every few years.

Headaches can range in frequency and severity of pain. Some individuals may
experience headaches once or twice a year, while others may experience
headaches more than 15 days a month. Pain can range from mild to disabling
and may be accompanied by symptoms such as nausea or increased sensitivity
to noise or light, depending on the type of headache.

With a headache-certified physician leading the program, Aurora is committed
to the multidisciplinary and collaborative treatment approach to headaches
and migraines.

Treatment

Information provided by the National Institute for Neurological Disorders
and Stroke

When headaches occur three or more times a month, preventive treatment
is usually recommended. Migraine treatment is aimed at relieving symptoms
and preventing additional attacks. Drug therapy, biofeedback training, stress
reduction, and elimination of certain foods from the diet are the most common
methods of preventing and controlling migraine and other vascular headaches.
Drug therapy for migraine is often combined with biofeedback and relaxation
training. The first step in caring for a tension-type headache involves treating
any specific disorder or disease that may be causing it. A physician may
suggest using analgesics, nonsteroidal anti-inflammatory drugs, or
antidepressants to treat a tension-type headache that is not associated with a
disease. Treatment options for cluster headaches include medication,
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PATIENT STORY:
Annette Wick
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Seizure Control Means Quality of
Life for One Young Woman

“He wanted the RIGHT prescription cocktail, not just A prescription
cocktail,” said Donna.

A visit with an epilepsy specialist at Aurora BayCare has vastly improved
one young woman’s quality of life.

Although Annette still has around two seizures daily, life is a lot better,
“This is a very hard epilepsy to manage. It is very unlikely that she is going
to be seizure free, but we try our best to limit the more dangerous ones,”
said Dr. Whitton.

Annette Wick is a 24-year-old with both epilepsy and an undiagnosed
genetic syndrome. She started having seizures at age seven and has
been seeing neurologists ever since. She’s had atonic seizures (also
known as drop attacks), convulsive seizures, and complex partial seizures.

Donna was grateful, “He’s had the most success, I would say, with
treating Annette.”

DR. WHITTON

For years her condition was manageable, but then
the seizures started picking up. By her early 20s,
Annette was having frequent drop attacks, suddenly
losing consciousness and falling to the floor.
Eventually the drop attacks became near daily
occurrences, and she began wearing a helmet to
prevent brain damage. At one point, she fell on a
heat register and cut her face. “She could have lost
an eye,” said Annette’s mom, Donna Wick.

“You know, you can’t bubble wrap the girl. We’re seeing that this is the
best quality of life that she’s had for quite a while,” said Donna. “She isn’t
falling anymore.”

Then, in fall of 2016, Annette was seen by Dr. Shawn Whitton, the new
epileptologist at Aurora BayCare.
Donna noticed right away how Dr. Whitton interacted with Annette.
“Some doctors are scared of her, but he was so welcoming,” Donna said.
Donna also appreciated being sought out as an active player in Annette’s
care, whereas previous providers were often content to communicate
with the staff at Annette’s group home.
“It was the first time we had a doctor who said, ‘I want to talk to the
mother.’ He was one of the first ones who’s done that for me,” Donna said.
“He wanted to find out what drugs had been tried and with what success.
He was truly open to listening to what I had to say.” Dr. Whitton changed
Annette’s meds, weening her off some that could actually worsen
her epilepsy and shifting toward others more targeted to her		
particular condition.

“ New therapies and
surgical techniques make it
possible to control seizure disorders
once thought to be untreatable. ”
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NEURO
OPHTHALMOLOGY
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Treatments for neuro-ophthalmic disorders include:

American Academy of Ophthalmology
Achievement Award physician department
that specializes in neurosurgical and
orbital disorders.
Partnering with neurosurgeons and otolaryngologists,
our neuro-ophthalmology specialists treat neurosurgical/orbital
disorders that require a multidisciplinary approach. They provide
their patients with the best medical evaluation available by
thoroughly discussing with them their options and helping them
make the best possible treatment decisions for their health care
goals and quality of life.

• Eye muscle surgery • Optic nerve fenestration
• BOTOX® for eyelid spasms • Eyelid surgery

Partnering with neurosurgeons and
otolaryngologists, our neuro-ophthalmology
specialists treat neurosurgical/orbital disorders
that require a multidisciplinary approach

Our team treats the full spectrum of oculoplastic and neuroophthalmic disorders including surgery for eyelid abnormalities and
skin cancers, eye socket tumors, reconstruction, and treatments for
tearing or dry eye problems.

Conditions treated include:
Anisocoria

Migraine

Anterior Ischemic
Optic Neuropathy (AION)

Myasthenia Gravis

Double Vision

Optic Nerve
Sheath Meningioma

Drusen

Optic Neuritis

Eyelid Myokymia

Photophobia

Hemifacial Spasm

Pituitary Tumor

Horner Syndrome

Progressive Supranuclear Palsy

Homonymous Hemianopia

Tearing

Idiopathic Intracranial
Hypertension

Thyroid Eye Disease

Microvascular Cranial Nerve 		
Palsy

Transient Visual Loss
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SPINE
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Complete management for spine conditions

AT A
GLANCE

Four out of every five Americans struggle with neck or back pain
due to an accident, injury, or just everyday wear and tear. This is pain
that often makes it hard to enjoy work and hobbies.
Aurora spine care is a comprehensive approach for a full range of
spinal conditions, including injuries, degenerative conditions, spinal
fractures, and tumors.
We offer the most advanced spine care available for back pain and
neck problems, and are recognized as innovators in the region.
We were the first to use minimally invasive spinal fusion and artificial
disc replacement to treat degenerative disc disease. In addition, we
offer complete management for spine conditions—everything from
common low back pain and disc problems to spinal injuries and
tumors. Our treatments include minimally invasive surgery, spinal
reconstruction, and fusion procedures.
Aurora’s comprehensive back and spine programs make it easier
for you to get back to the things that matter most. With a care
coordinator to guide your care, you’ll be connected to an integrated
team of specialists all working together on your personalized
treatment plan.

Aurora saw over

22,000 emergency

room and urgent care visits related to
neck and back pain in 2016.

Did you know that 80% of people experience back
pain at some point in their lives?
In its first year, the Aurora Back and Spine program saw
about 800 new patients; that number more than
tripled last year to 2,415.
If you’re suffering from a spinal disease or have
developed back pain as a result of a tumor or an injury,
our talented team of specialists can help you regain
mobility and return to your daily activities.
Risk-adjusted cost per case for spine patients in 2016
was $17,331 with an expected cost of almost $25,000,
proving our team’s efficiency in surgical technique.
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COMPLETE MANAGEMENT FOR SPINE CONDITIONS

SPINE CERTIFICATION

In most cases, back pain can be managed
conservatively and without surgery. The
Aurora Back and Spine program provides
treatments that will help provide a solution
to back pain and get patients back to an
active life.

Meeting higher standards to support better
outcomes for spine care

With one call you’ll be connected to our team of experts led by a spine
nurse navigator that guides patients through every step of the diagnosis
and treatment process.
Aurora Back and Spine is part of an integrated health system that
treats not just the spine, but the patient as a whole person. Combining
medical history, lifestyle, and patient desire, we seek treatment options
that work best for each individual patient.
Treatment options might include the following:
•

Physical therapy

•

Behavioral health

•

Orthopedics

•

Neurosurgery

•

Pain management

•

Integrative therapy

•

Chiropractic

Certified Spine Center
AURORA SHEBOYGAN MEMORIAL MEDICAL CENTER
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Joint Commission Spine Center Certification confirms that a spinal surgery
program is in compliance with consensus-based national standards, has an
effective and consistent use of appropriate, evidence-based clinical practice
guidelines for the discectomy, laminectomy and spinal fusion patient
populations, and performs a collection and analysis of spinal-specific
performance measures.

Aurora performed more optical robotic

spine surgeries in 2016 than anyone

else in the world.
		

DATA

BCBS BLUE DISTINCTION®

Evaluating what matters
Blue Distinction Center designations are awarded to health care facilities
based on a thorough, objective evaluation of their performance in the areas
that matter the most—quality care, treatment expertise, and overall patient
results, just to name a few. The criteria are established with the help of
expert physicians and medical organizations. Blue Distinction Centers have a
proven history of delivering better quality and results than healthcare
facilities without these recognitions.
Blue Distinction Centers for Spine Surgery provide comprehensive inpatient
spine surgery services, including discectomy, fusion, and decompression
procedures. Research confirms that designated health care facilities in this
area have lower readmission rates and fewer reoperations than
non-designated facilities.

BCBS Blue Distinction Centers:

AURORA BAYCARE MEDICAL CENTER
AURORA MEDICAL CENTER GRAFTON
AURORA ST. LUKE’S MEDICAL CENTER
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CEREBROVASCULAR
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The American Stroke Association reports that as of 2016, stroke
is the 5th leading cause of death in the United States, killing
almost 133,000 people every year and accounting for 1 in every
20 deaths. Fortunately, though, due to advanced treatment
options and the early recognition of stroke symptoms, the past
10 years have seen a decline in the death rate from stroke by
about 29%. Still, almost 800,000 people have a stroke every
year, which averages to about one stroke every 40 seconds.
The decreased rate of stroke mortality over the past decade is
a major improvement in population health seen in both sexes
across all age groups and races, and is largely contributed to
significant improvements with cardiovascular risk factors and
their control. Better management of diabetes and high
cholesterol, along with smoking cessation and advanced
hypertension treatments, also appear to have led to the
decline in the number of stroke deaths.
Despite the decline in deaths, the incidence of stroke is still on
the rise and continues to be the leading cause of long-term
disability in the United States. Furthermore, the prevalence of
stroke in younger adults and even children has increased,
leading to focused efforts on not only the management of stroke
risk factors, but also the education of the population to identify
stroke symptoms and seek treatment sooner.
In order to maintain our status as a leader in cutting-edge stroke
treatments and protocols, Aurora Health Care has established
evidence-based care guidelines at all sites for all types of stroke
patients to ensure that best clinical practice is followed to
maximize recovery, manage complications, and prevent 		
long-term deficits for our patients. In addition to that, highly
functional and specialty-trained teams have been constructed
to guide the stroke patient through every step of the diagnosis
and treatment process including neuroscience nurse		
practitioners, physician assistants, nurse navigators, and		
trained stroke responders. Coupled with an extensive team
of stroke, cerebrovascular, endovascular and critical care		
neurologists, stroke patients at Aurora are cared for by the
highest level of medical professionals available.

AT A
GLANCE
COST OF STROKE IN THE U.S.

11,221
strokes
2016
State of
Wisconsin

PREVALENCE OF STROKE

Stroke kills
someone in
the US

every 4 minutes

2,096
strokes
2016
Aurora
Healthcare

Stroke is the
leading cause
of long-term
disability
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STROKE CERTIFICATION

Meeting the highest standards to support better
outcomes from stroke care

•

ICU/neuroscience ICU facilities and capabilities

Primary Stroke Certification

•

Experience and expertise treating patients with large		
ischemic strokes, intracerebral hemorrhage, and			
subarachnoid hemorrhage

Primary Stroke Certification recognizes hospitals for going above and
beyond the standard of care to ensure ischemic stroke patients receive
the highest level of treatment options and quality measures. Eligibility
standards set by the American Heart Association/American Stroke
Association include:
•

A dedicated stroke-focused program and stroke unit

•

Staffing by qualified medical professionals trained in stroke care

According to the Joint Commission, the governing body currently
certifying the Primary and Comprehensive Stroke Centers at
Aurora Health Care, the benefits of certification reach far beyond
the accolades of the accomplishment. Certification signifies that our
organization has established a consistent approach to stroke care,
reducing the risk of error, and has maintained a consistently high level of
quality using effective data-driven performance improvement.

•

Individualized care to meet stroke patients’ needs

Get With the Guidelines®

•

Coordination of best practice care of stroke patients
across the continuum

•

Participation in stroke care databases to continually assess
improve quality of care

Aurora Health Care is proud to be a participating member in the American
Heart Association’s (AHA) Get With The Guidelines® (GWTG) program,
an in-hospital database that promotes consistent adherence to the latest
scientific treatment guidelines for stroke. Participation with GWTG allows
our stroke care teams to have constant access to the most up-to-date
research and scientific publication, gives us a competitive advantage in the
healthcare marketplace, and provides performance feedback reporting for
continuous quality improvement.

Comprehensive Stroke Certification
In addition to this, some hospitals may also qualify for Comprehensive
Stroke Certification, which meets all of the primary requirements, as well
as sets the highest standards for the care of hemorrhagic patients and the
most complex stroke patients eligible for surgical or endovascular
intervention. Comprehensive eligibility standards include the following:
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Target Stroke Awards
•

Target: Stroke Honor Roll: Time to therapy within 60 minutes in 50%
or more of acute ischemic stroke patients treated with IV tPA

•

Availability of advanced imaging techniques, including MRI/MRA,
CTA, DSA, and TCD

•

Target: Stroke Honor Roll–Elite: Time to therapy within 60 minutes
in 75% or more of acute ischemic stroke patients treated with IV tPA

•

Availability of personnel trained in vascular neurology, 		
neurosurgery, and endovascular procedures

•

•

24/7 availability of personnel, imaging, operating room, and
endovascular facilities

Target: Stroke Honor Roll–Elite Plus: Time to therapy within 60
minutes in 75% or more of acute ischemic stroke patients treated
with IV tPA & DTN, within 45 minutes in 50% of acute ischemic stroke
patients treated with IV tPA

PRIMARY STROKE CENTERS:
Aurora BayCare Medical Center			Gold Plus,
							TARGET Stroke
							Honor Roll-Elite Plus
Aurora Medical Center Manitowoc County
Aurora Medical Center Oshkosh 			

Gold Plus

Aurora Sheboygan Memorial Medical Center
Gold Plus,
							TARGET Stroke
							Honor Roll-Elite
Aurora Medical Center Summit			
Gold Plus,
							TARGET Stroke
							Honor Roll-Elite Plus
Aurora Medical Center Grafton			
Gold Plus,
							TARGET Stroke
							Honor Roll-Elite
Aurora St. Luke’s Southshore			

Of the 44 certified
stroke centers in the
state of Wisconsin,
Aurora Health Care
locations are 13 of
them, representing
about 30% of the
entire state.

Gold Plus

Aurora Sinai Medical Center			
Gold Plus,
							Target Stroke
							Honor Roll
Aurora West Allis Medical Center			

Gold Plus

Aurora Memorial Hospital of Burlington		

Gold Plus

Aurora Medical Center Kenosha			

Gold Plus

Aurora Lakeland Medical Center			

Gold Plus

COMPREHENSIVE STROKE CENTERS:
Aurora St. Luke’s Medical Center			
Gold Plus,
							TARGET Stroke
							Honor Roll-Elite Plus
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BY THE NUMBERS
THROMBOLYTIC THERAPY

OUTPATIENT STROKE VISITS

TYPE OF
STROKE
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MEDIAN TIME DOOR TO NEEDLE
00 05 10 15 20 25 30 35 40 45 50

AHC		

50 Mins

WISCONSIN

53 Mins

AHC		

44 Mins

WISCONSIN

45 Mins

AHC		

49 Mins

WISCONSIN

50 Mins

AHC		

50 Mins

WISCONSIN

52 Mins

DOOR TO NEEDLE
Q1

Q2

WITHIN 45
MINUTES

23.5%

55.6%

WITHIN 60
MINUTES

70.6%

85.2%

Q3

Q4

2016

41.4%

40%

41.8%

89.7%

88%

84.7%
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NEUROENDOVASCULAR INTERVENTION
Neuroendovascular conditions are complex conditions of the central nervous system—the brain, spine, and peripheral nerves. In the past, no treatment may have
existed. Today, the neuroendovascular subspecialty makes it possible for highly trained physicians to diagnose and treat these conditions, including strokes,
aneurysms, and arteriovenous malformations, in addition to a variety of other diseases.
Our expert physicians at Aurora St. Luke’s Medical Center and Aurora BayCare Medical Center perform the very latest procedures using first-in-class minimally
invasive technology. Also known as endovascular surgical interventional neurology or neurointerventional surgery, neuroendovascular care allows physicians to
use high-tech radiology to view, isolate, and treat the source of a wide variety of central nervous symptom conditions.
Our innovative treatments are designed to save lives and minimize disability. High-tech, less-invasive procedures also have the benefit of shorter hospital stays
and easier recovery periods.
Time matters after a stroke. After a certain window of time has passed, patients who have had an ischemic stroke are no longer suitable to receive medication
designed to break up the clot. With 24/7 access to neurointervention care, stroke patients at Aurora can be treated by a team that specializes in stroke care. For
specific cases, a specially trained physician can use minimally invasive procedures to enter the affected brain vessels and break up or pull out the blood clot.

Primary Core Measures
AHC vs. WI Hospitals

%

AHC

WI HOSPITALS

100

0

STK-1:

VTE
Prophylaxis
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STK-2:

Antithrombotics
at Discharge

STK-3:

Anticoagulation
at Discharge

STK-4:

IV t-PA
Administration

STK-5:

Antithrombotics
Day 2

STK-6:
Statin on
Discharge

STK-8:

Stroke
Education

99.5

99.9

94.9

97.6

97.1

98.9

99.2

99.0

90.9

93.5

97.2

98.3

99.4

100

98.5

99.4

50

STK-10:

Assessed for
Rehabilitation

Comprehensive Core Measures
%

AHC

AHC vs. AII CSC

AII CSC

100
CSTK-7:

Median Time
to Revascularization

118
mins

50

121
mins

0

CSTK-1:
NIHSS

CSTK-2:

mRs at 90-days

CSTK-3:

Severity
Measurement
SAH/ICH

CSTK-3a:
Hunt/Hess
for SAH

CSTK-3b:
ICH Score

CSTK-4:

Reversal
Initiation ICH

CSTK-5:

No
Hemorrhagic

CSTK-5a:

No Hem Trans
for IV t-PA

CSTK-5b:
No Hem Trans
for IA t-PA

CSTK-6:

Nimodipine
Administered

79.1

69.6

74.1

100

87.4

91.3

97.1

100

93.1

96.6

88.4

100

45.4

89.2

53.2

92.5

48.1

90.1

86.4

98.0

74.1

92.7

CSTK-9:

CSTK-8:

Median Time
to Skin Puncture

62.5
mins

81
mins

TICI Post
Treatment Grade
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BY THE
NUMBERS
Mortality of hemorrhagic stroke
was 6.47%, with risk-adjusted
expectation at 7.55%
Overall readmission rate for
stroke was 7.17%, with risk-adjusted
expectation at 8.82%
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INTERVENTIONAL PROCEDURES

31.9%

54.4%

Elective
Carotid
Intervention

Cerebral
Angiogram

7.3%

2.0%

Aneurysm
Coiling

Carotid Angio
w/ Interventon

2.7%

0.8%

Cerebral
Embolization

WADA

0.9%

Aneurysm
Clipping

In a recent study by the American Heart Association and the American Stroke Association,
the FAST (Face Arms Speech Time) stroke recognition tool identified anywhere from 69% to 90% of strokes.
However, FAST missed up to 40% of those with posterior circulation events and also does not include the
cardinal sign of hemorrhagic strokes—a sudden onset of the worst headache of someone’s life. Further, it
was found the use of BE FAST (Balance Eyes Face Arms Speech Terrible headache) could reduce the missed
stroke diagnoses to as low as 4.4%. For these reasons, in October of 2016, Aurora adopted the more inclusive
BE FAST stroke recognition tool. This change will be used in the foreseeable future to more comprehensively
educate our communities on the signs, symptoms, and response to stroke.

A stroke is an emergency.
Every minute counts.
B.E. F.A.S.T
BALANCE: Sudden loss of balance or coordination
EYES: Sudden change in vision; loss of vision, blurry vision or double vision
FACE: Facial droop , uneven smile
ARMS: Arm or leg weakness or numbness
SPEECH: Slurred speech, trouble speaking , trouble understanding speech
TERRIBLE HEADACHE: Sudden onset of a terrible headache
Call 911. Get to the hospital immediately. Have the ambulance take you to the nearest hospital with a certified stroke center.
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NEURO
CRITICAL CARE
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TERTIARY ACCESS PROGRAM
Connecting physicians to physicians to expedite patient transfer
Our goal is to find better treatment options that result in better patient
outcomes. Aurora Health Care can facilitate admission of patients who need
immediate attention for stroke or cerebral hemorrhage, including connection
to our Neuro Intensive Care Units.

Inside our Neuro ICU, our patients receive care
around the clock and are closely monitored by
expertly-trained specialists.
Our neuro critical care team is unique in that they actively treat and oversee
an entire patient population instead of simply performing consultative work.
In addition, they work in day-to-day collaboration with our neurology,
neurosurgery, and endovascular teams for a truly comprehensive approach
to critical patient care.
Our neuro critical care team features:
•
27-bed Neuro ICU
•
Significant neuro monitoring
- 24 hr. EEG, ICP, EVD
- 24 hr. IN-HOUSE intensivist coverage
- Fellowship-trained neurocritical care physicians
•
All Neuro ICU nurses are NIH-certified and specially neuro-trained
•
24/7 Neurosurgery coverage with backup
•
24/7 Endovascular neurology/interventional neuroradiology coverage

3,956 transfers were made in 2016
through the TAP system
848 were
neuroscience-related (21.4%)

The Tertiary Access Program connects experts by phone, internet, and mobile
technologies. It allows physicians to work with real people (hospitalists,
intensivists, or specialists), exchange information, access e-ICU care, and
expedite patient transfers.
The TAP’s dedicated critical care-trained nurses connect physicians directly
to the appropriate clinical personnel, creating a streamlined transfer process
that results in superior quality and service for our patients. TAP connects
transferring physicians to admitting physicians for direct communication,
contacts appropriate ancillary hospital staff to expedite admitting processes,
and follows up with the transferring physician on admission status and closes
communication loop by sending discharge summary to referring physician.

Neuro ICU Admissions - 707
Average LOS - 5.75 days

53%

17%

20%

Ischemic
Stroke

Late
Effects

TBI/
Trauma

2%

6%

1%

SAH

ICH

SDH

		
In 2016, our Neuro ICU team took our Foley catheter infection rate from 16% to 2%.
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NEURO
PSYCHOLOGY

70

Evidence-based, holistic, and therapeutic approaches to
neuropsychological evaluation that is individually-centered

Neuropsychology
Visits

and culturally sensitive. Our team strives to create a supportive,
collaborative assessment process whereby patients and their
families learn about cognitive functioning and strategies to
manage cognitive/cognitive-behavioral difficulties in
everyday living.

We specialize in:

Neuropsychology is a division of Aurora Health Care that focuses on
understanding patients’ cognitive and functional abilities as they relate to
the brain. Common abilities assessed include general intellect, attention,
memory, language, visual spatial skills, and executive functions. A patient’s
emotional, behavioral, social, and when relevant, academic functioning is
also assessed. Neuropsychologists diagnose a range of brain-based 		
disorders across the life span, from preschool-aged children with
developmental disabilities to adults with question of dementia. Evaluations
can also help to determine how neurological conditions such as 		
concussion, epilepsy, brain tumor, and multiple sclerosis are affecting daily
functioning. Following an evaluation, neuropsychologists provide education
to the patient and family, and generate recommendations to help improve
the patient’s quality of life.

•

Neuropsychological evaluation

•

Cognitive rehabilitation

•

Psychotherapy

•

Inpatient consultation

•

Liaison services with adult populations

In addition to outpatient services, neuropsychology serves as part of the
ANII multidisciplinary team to provide comprehensive clinical care in a
hospital based setting. Neuropsychologists perform pre- and post-surgical
evaluations, help determine prognosis and risk for cognitive morbidity
following a range of medical interventions, conduct intracortid sodium
amytal procedures (Wada tests) to determine language and memory
lateralization prior to surgery, and assist with intraoperative cognitive
monitoring. Neuropsychologists often follow patients with hydrocephalus,
brain tumors, and other neurological conditions as they undergo prolonged
treatment (i.e., spinal taps, shunting, radiation, chemotherapy) to assess for
possible change over time.

1951

Areas of treatment include:
•

Neuro-oncology

•

TBI

•

Stroke

•

Dementia

•

Parkinson’s disease

•

MS

•

Epilepsy

•

Medical and mental health conditions that may
impact cognition, performance validity testing,
rehabilitation psychology/neuropsychology,
and psychotherapy

Adult

513
Pediatric

Neuropsychology at Aurora Health Care has seen rapid growth over the last
10 years. There are currently 5 neuropsychologists, with 2 more joining in fall
2017 (5 focused on adults and 2 focused on children and adolescents). In
addition to keeping up with the most advanced, evidence-based practices,
our neuropsychologists conduct original grant-funded research and
participate in interdisciplinary clinical research headed by the Aurora
Research Institute and the Aurora Neurosciences Innovation Institute.
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NEURO REHAB
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Within Aurora Health Care’s network of rehabilitation clinics, 30 sites
feature specialists skilled in treating neurological disorders and injuries.
Site-specific offerings range from physical, occupational, and/or speech
therapy to a comprehensive team approach for effectively caring for
individuals diagnosed with high-level neurological impairments.
A number of our clinics have received specialty
accreditation for stroke rehabilitation from the
Commission on Accreditation of
Rehabilitation Facilities (CARF). To help restore and improve function
needed for activities of daily living, including: mobility, strength, balance,
swallowing, speech, memory, thinking, and coping. By returning patients to
activity following a life-altering event, we help to preserve
their independence.
Specialized clinical staffing includes:
•

Occupational therapist

•

Physiatrist

•

Physical therapist

•

Psychologist

•

Recreational therapist

•
Specialists
		 - Nursing
		 - Social work
		 - Integrative medicine

•

Speech pathologist

•

Vocational therapist

Conditions/diagnoses addressed through outpatient neuro therapy:
•

Parkinson’s disease

•
Speech
		 - Communication disorders
		 - Cognition disorders
		 - Swallowing
•

Spinal cord injury

•

Stroke

•

Amyotrophic lateral sclerosis (ALS)

•

Bell’s palsy, neuromuscular facial retraining

•

Brain injury, concussion

•

Balance, vestibular

•

Fall risk

•

Gait

•

Multiple sclerosis

•

Neurological conditions

89

IP rehab beds
across system

5

IP rehab programs in
SE Wisconsin, one of them
is the largest in state
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TREATMENT
To gauge improvement from therapy, a patient baseline is created
using a Functional Independence Measure. This measurement defines
how much help the patient needs to complete certain tasks associated
with activities of daily living (ADL). At the time of discharge, nearly
100 percent of patients have shown documented improvement.

Average treatment length resulted in
a 51.5% restoration of function at the
completion of therapy and nearly 100%
had documented improvement

Appointment length and number of visits depend on the severity
of the neurological disorder or impairment. Treatment may also
involve advanced rehab technology:
•
•
•
•
•
•

Nintendo Wii system
Video Stroboscopy
VitalStim therapy
Bioness NESS, LiteGait mobility devices
DynaVox
Kay Digital Swallowing Workstation

Additionally, the following specialty programs, classes and
support group sessions are offered at various clinic locations:
•	Cognitive Rehabilitation and Activities Program
- Designed for patients in early stages of dementia
and cognitive decline.
		 - Speech therapy components: Memory, language, social
interaction, reasoning, and problem solving.
		 - Occupational therapy components: Visual perception,
acuity, activities of daily living, medication management,
financial management, home safety, and cognitive skills
related to driving.
•
•
•
•
•
•

Brain Workout Class
Driver Readiness Program
Stroke at Mid-life Support Group
Parkinson’s Disease Skills Class
Stepping On: Fall prevention, strength, balance
Big & Loud Therapy Program: Parkinson’s disease patients

As treatment is driven by doctor referral, sharing additional education and
documented outcome statistics with physicians could have a definite impact
on patient levels.
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IP Neuro Rehab Patients
Stroke 						488
Brain							276
Neurologic (MS, PD, GB, neuropathy, etc.)		

102

Spinal Cord						116

BY THE
NUMBERS

4,923
outpatient
referrals to
neuro rehab

1,611

number of patients
served (IP rehab)

12.6

DAYS
average length
of IP stay

52.4

average age
in OP setting

30

outpatient
rehab clinics

98%

5

IP hospitalbased
clinics

79%

overall
satisfaction
with care

discharge to
community
(competitors
are 73.8%)
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AURORA
RESEARCH
INSTITUTE
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Deep brain tumors, areas of bleeding, and cysts that were once

considered too risky to operate on by many are now often
removed through a precise and patient-specific corridor with
Aurora Neuroscience Innovation Institute (ANII)’s unique,
integrated surgical techniques.
Led by neurosurgeon Amin Kassam, MD, ANII includes a multidisciplinary clinic, education suite, neuroanatomical laboratory, and four
neurosurgical operating suites featuring first-in-the-world technology
at Aurora St. Luke’s Medical Center.

Surgical Techniques
A bedrock of innovative research combined with
collaboration among the neuro-oncology multidisciplinary team translates into increased access
to innovative minimally invasive techniques.
These techniques offer patients hope for better
surgical results and improved long-term health
outcomes. They also minimize long-term complications as a result of their tumor or surgery.
AMIN KASSAM, MD

BY THE
NUMBERS

129

new subjects
enrolled in 2016 neurosciences
cllinical trials

25

neurosciences
publications and
abstracts in 2016

Directed Therapy Options

Neurosurgeons collect and preserve the brain
AURORA NEUROSCIENCES tissue they remove for pathology, molecular,
and genetic evaluation. These samples provide
opportunities to study new treatments for patients. The ability to
capture, grow, and use the tumor tissue in research enables the team
to study new targets for treatment that can be brought back to the
patient in an individualized manner, epitomizing Aurora’s commitment
to precision medicine.
VICE PRESIDENT,

34

10

published manuscripts
or book chapters

neurosciences
research studies as of
December 31, 2016

15

published abstracts

surgical pathway before a brain surgery procedure begins, which may translate
into improved outcomes and a faster recovery.

Dynamic Navigation
Neurosurgeons use a GPS-like system that gives them real-time guidance
deep within the brain. Patients can see their brain tumor removal on the same
computer screen that their surgeons use to track the movements of their		
surgical instruments.

All of this patient and correlated cell data is then compiled into a
novel image-driven database with the goal of capturing enough data
to predict outcomes. Aurora was the first institution in the world to
install and implement this specific image-driven informatics system.

Safe Access

Mapping

High-Definition Optics

An invaluable tool for Aurora’s neurosurgeons, brain mapping depicts
aspects of a tumor and surrounding healthy tissue with enhanced
clarity rendered in a three-dimensional space. This imaging 		
technology allows surgeons to plan a patient-specific, real-time

This technology allows neurosurgeons to differentiate tissue types with 		
unprecedented clarity. Being able to separate diseased tissue from healthy
tissue makes it possible to successfully remove what would otherwise be 		
considered inaccessible brain tumors, cysts, or other difficult-to-see growths.

Aurora uses a specialized and innovative tool that minimizes damage to surrounding tissue by allowing neurosurgeons to safely displace the natural folds
of the brain as they advance to the target site.
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The robotically-operated video telescopic-microscopy system (ROVOT-m)
is a novel optical tool that consists of an optical system connected to a
robotic arm that has the ability to maneuver along the surgical field in a
hands-free, command-prompted interface.

INNOVATIVE IMAGING
TECHNIQUES
DRIVE SURGICAL STRATEGIES
Minimally invasive brain surgery requires
detailed planning to avoid white matter tracts
and areas of the brain that control function.
Neurosurgeons and neuroradiologists at Aurora Neuroscience Innovation Institute (ANII) use
advanced magnetic resonance imaging (MRI)
techniques called diffusion tensor imaging
(DTI) and functional MRI (fMRI) to devise
patient-centered strategies.

Fig. 1

Fig.2

White matter pathways connect one area of
the brain to another and DTI allows those
connections to be visualized (Figure 1).
Locating areas of the brain activated during
language and motor tasks are possible
noninvasively with fMRI. This technique relies
on changes in blood flow to specific areas of
the brain caused by active neurons. Changes
in blood flow are elicited by having the patient
conduct motor, sensory, visual, auditory, and
language tasks. fMRI maps of functional activation correlating with specific
areas of the brain are created using statistical processing (Figure 2).
The DTI and fMRI maps are then carefully aligned so that the relationship
between, for example, the tumor, white matter tracts, and areas of the brain
that control function, can be visualized simultaneously. Based on this information, a route to the tumor is designed to minimize impact of the surgery.
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The culmination of these integrated technologies allows for many patients
to have surgery while awake. Many patients interact on their phones or
smart devices during surgery, and many go home the next morning. Having
patients awake permits detailed neurocognitive evaluation throughout the
procedure. This intensive monitoring provides a margin of safety difficult
to achieve when the patient is asleep.

Fig. 3

Fig. 4

“The combination of DTI, fMRI and anatomic
MRI provides a road map for surgery and helps
determine the safety and feasibility of 		
operating on the lesion,” said Richard Rovin,
MD, medical research director.
This innovative imaging technique proved
useful in a patient with a tremor and weakness
in her left arm. After finding a large metastatic tumor adjacent to a part of the brain
controlling motor function, the team used DTI
and fMRI to identify the white matter tracts at
risk with surgery (Figure 3). Functional areas
at risk included the left hand, face and area
that contributes to movement and sensation
(Figure 4).
A precise trajectory was designed to avoid
the tracts and functional areas. With this plan,
the patient underwent surgery while awake
to have the tumor removed. After surgery, the
patient’s left arm strength improved.

The ANII team is studying the technique of
fusing DTI and fMRI images. Preliminary data
released in 2016 show that the technique is
highly reliable in allowing to more fully remove tumors adjacent to
functional areas of the brain with very low complication rates. The team is
further validating the approach using technologically advanced methods of
testing the patient’s speech, cognition and motor systems during the awake
surgeries. Neuroradiologist Jonathon E. Jennings, MD, is the principal
investigator for the study.

Clinical trial highlights
Monitoring cardiac rhythms in stroke
Development of atrial fibrillation, an abnormal heart rhythm, is a risk for people
who have had an ischemic stroke. Led locally by principal investigator Rehan
Sajjad, MD, researchers are comparing the incidence of atrial fibrillation
documented with an implantable continuous cardiac rhythm monitoring device
versus standard of care monitoring. Medtronic Inc. is sponsoring the Phase IV
trial (clinicaltrials.gov identifier: NCT02700945). Kate McPolin, BSN, and Lynda
Yanny, BSN, are serving as coordinators at Aurora St. Luke’s
Medical Center.

22

neurosciences clinical trials
open to accrual and follow-up as of Dec. 31, 2016

NeuroOncology
(7) 32%

Studying outcomes after stroke
Open at three Aurora sites, the Mild and Rapidly Improving Stroke Study 		
(MaRISS) is tracking outcomes of subjects who have suffered mild and rapidly
improving stroke (clinicaltrials.gov identifier: NCT02072681). Through this 		
American Heart Association study, sponsored by the University of Miami, 		
researchers will track the proportion of subjects not independent at 90 days
after a stroke. The study is supported by investigators/coordinators at each site:
•	Aurora BayCare Medical Center: James Napier, MD/Laura Thoreson
and Taylor Romdenne
•	Aurora Medical Center in Grafton: Rose Dotson, MD/Sue Truchan, BSN,
and Stacie Bishop

Neurosciences clinical
trial research at
Aurora Health Care
provides patients

with ACCESS to
investigational therapies
for brain cancer, stroke,
multiple sclerosis and
epilepsy.

Surgical
(6) 27%

Stroke
(4) 18%
Epilepsy
(2) 9%

129

Multiple
Sclerosis
(3) 14%

new subjects enrolled in
neurosciences clinical
trials in 2016

•	Aurora St. Luke’s Medical Center: Rehan Sajjad, MD/Carol Halliday, RN,
and Lynda Yanny, BSN

Targeting MS
In multiple sclerosis, immune cells attack nerve fibers in the central nervous
system, interfering with signals between the brain and the spinal cord. 		
An approved leukemia treatment called ofatumumab reduces their ability to
damage the central nervous system. Led by principal investigators
Akram Dastagir, MD, at Aurora St. Luke’s Medical Center and James
Napier, MD at Aurora BayCare Medical Center, researchers are comparing
the effectiveness and safety of ofatumumab versus the standard treatment
teriflunomide in patients with relapsing multiple sclerosis (clinicaltrials.gov
identifier: NCT02792218). Sponsored by Novartis Pharmaceuticals, the Phase III
study tests whether clinical trial participants treated with ofatumumab 		
experience fewer multiple sclerosis relapses. Carol Halliday, RN, is serving as
research coordinator at Aurora St. Luke’s and Alex Albers and Laura Thoreson
at Aurora BayCare.

Surgical
(101) 78%

NeuroOncology
(22) 17%
Stroke (3) 2%

Multiple
Sclerosis
(2) 2%
Interventional
Radiology
(1) 1%
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Translational highlights

Figfig.1
1.

A new way to generate
multiple tumor specimens
that display a patient’s
characteristics
Growing tumors for testing

Tissue collection studies

The spread of cancer to the brain from other primary tumors, such as breast
cancer, is occurring more frequently, creating an urgent need to identify the
underlying molecular factors and test drugs against those targets.

Development of genetically targeted diagnostics and therapies has increased exponentially in the past 10 years, in many ways
thanks to people who are willing to donate
To find these molecular targets, researchers need to understand how cancer
tissue after a medical procedure (see one
grows and spreads. One model to test this involves growing the tumors in
patient’s experience with tissue donation
scientifically engineered mouse avatars from human tumor cells.
on page 6). To conduct neurosciences
This can be challenging because sometimes the tumors fail to grow.
research, clinically sound and genetically
Postdoctoral fellow Amber LaCrosse, PhD, and a team at Aurora Research
diverse samples are required. NeuroInstitute determined a potential new way to generate multiple tumor
sciences researchers, in collabspecimens that display patient characteristics. They implant tumor
oration with Aurora Research
cells through the cerebral aqueduct, part of the brain’s 		
Institute’s Biorepository and
ventricular system, rather than the traditional method that
Specimen Resource Center,
utilizes the striatum, located toward the center of the brain.
have focused on screening
brain tissue samples
patients for viability of
were donated
“Patient-derived tumor models are difficult to generate; howin
2016
samples, obtaining conever, placing the tumor cells in a region that would facilitate
by Aurora
sent, and collecting these
their spread and allow cells to choose an appropriate growth
patients
specimens for neurosciences research.
niche may facilitate successful tumorigenicity,” said Dr. LaCrosse.
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Cells from the first-generation tumors were then used to grow
second and third generations of tumors. Testing of the tumor masses
confirmed that the third-generation cells retained key characteristics of the
original patient tumor (Figure 1).
Using this unique implantation site to grow second- and third-generation
tumors with distinct characteristics may help with the diagnosis and
treatment of patients with brain metastases in the future.
Dr. LaCrosse’s findings were made possible by a grant from the Vince
Lombardi Cancer Foundation.
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Patients are becoming more aware of the need for tissue
donation to boost clinical research. A total of 82 brain tumor
tissue samples were donated in 2016 by willing Aurora patients. The effort to
obtain these precious samples is substantial. Over 90% of patients who are
approached for consent agree to participate. Of those consenting patients,
tissue collection occurs from 60% of them because sometimes the tumors
are too small and must all be used for clinical purposes.

Physician highlight
Mapping a route toward wellness
A member of a collaborative multidisciplinary team at
Aurora Health Care, neuroradiologist Melanie Fukui, MD,
helps provide a highly detailed road map for neurosurgeons prior to brain surgery using some of the most
advanced tools in imaging.
“We are fortunate at Aurora St. Luke’s to have the capital
and intellectual resources to make the most of advanced
imaging techniques, such as magnetic resonance (MR)
perfusion, MR spectroscopy and diffusion tensor imaging,”
said Dr. Fukui, who was named one of The Best Doctors in
America. Dr. Fukui has been with Aurora for nearly three
years and has 25 years of clinical experience.
Dr. Fukui and researchers at Aurora Neuroscience Innovation Institute are studying diffusion tensor imaging, a tool
that provides detailed imaging of biological tissue (see
page 48), and a three-dimensional modeling technique
that can provide visualization of neural tracts when treating abnormal tissue in the brain, or lesions.
These state-of-the-art, advanced imaging techniques are
routinely available to Aurora patients. This mapping technology is only one unique aspect to the patient-centered
care plans that have made Aurora a national destination
for brain surgery (see page 53). Multidisciplinary collaboration for each patient occurs
between neuroradiologists, such as Dr. Fukui,
neurosurgeons, neuro-oncologists, radiation
oncologists, medical oncologists, palliative
care specialists, neuropsychiatrists, advanced
practice providers, and care coordinators.

a critical neural structure that is producing symptoms,
or cyto-reduction, in order to make radiation and chemotherapy more effective options,” Dr. Fukui said. “The
challenge then becomes designing a plan to achieve the
surgical goal with the least disruption of normal surrounding tissue and the greatest preservation of neurological
function. Sometimes it is better to take the long way,
rather than the shortest route, in order to maintain critical
structures.”
Dr. Fukui appreciates the face-to-face collaboration that
she has experienced at Aurora. With the introduction of
electronic images, such as picture archiving and communications systems, she maintains that, in other institutions,
this face time has become less common. The combination
of state-of-the art imaging with true collaboration ensures
that the patient obtains the best possible care.
Dr. Fukui helps map treatments for some aggressive and
challenging cases, necessitating a need for a bench-tobedside approach. Dr. Fukui says that, in the future, precision molecular imaging combined with tumor-specific
agents may boost both neuroimaging and treatment.

DR. FUKUI
helps provide a road
map for neurosurgeons
prior to brain surgery
using some of the

MOST
ADVANCED
IMAGING
TOOLS.

“We are hopeful that applying new techniques to these
patients’ care will translate into treatment modifications
that improve outcomes,” Dr. Fukui said.

“We first consider the patient’s treatment
goals and functional priorities, as well as
whether the surgical goal is complete resection, tissue diagnosis, decompression of
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Researcher highlight
Breaking down barriers in brain cancer
With almost 20 years in the laboratory, senior research scientist
Santhi Konduri, PhD, is on the cusp of translating her research into
a clinical trial, providing a new investigational option in the fight
against brain cancer.
Since joining Aurora Research Institute in July 2013, Dr. Konduri
has focused on combining existing chemotherapy drugs with
drugs approved for other indications in an attempt that may
synergistically increase survival and decrease toxic effects in
hard-to-treat cancers.
With Aurora Cancer Care Research Awards made possible by gifts
from Vince Lombardi Cancer Foundation, Dr. Konduri and her team
evaluated the drug disulfiram as part of a combination therapy
for breast and pancreatic cancers. The interest in disulfiram was
sparked because it is an FDA-approved drug.
The combinations significantly decreased tumor cell growth in both
pancreatic and breast cancers.
Applying these initial results, Dr. Konduri is testing combinations on
brain cancer, specifically glioblastoma multiforme, a rapidly growing
and aggressive brain tumor.
“Some of these patients are dying within six to nine months of their
diagnosis,” Dr. Konduri said. “It is too difficult for many drugs to
penetrate the brain, which makes them ineffective.”
Disulfiram can cross the blood–brain barrier. But it needs help.
“These cell membranes are tougher, but when we combined
copper with the disulfiram, we were more easily able to kill the
primary brain tumor cells,” Dr. Konduri said. “Disulfiram combined
with copper forms another compound that is able to kill the brain
cancer cells effectively.”
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“If you are able to decrease the amount of this drug,
you can also reduce the side effects of the chemotherapy
drugs,” Dr. Konduri said. “We want see if we can decrease
side effects so that these people can lead better lives
without as many complications.”

“Her passion for finding alternatives to current therapeutic
options is evident in everything she does in the lab,”
With the addition of copper, less disulfiram is needed; high levels of disulfiram
may cause neurotoxicities, which destroys normal brain cells.
Taking the research further, Dr. Konduri added the chemotherapy drug
temozolomide, which is approved for treatment of glioblastoma multiforme.
“Next we want to
offer these potential
therapies to consenting subjects in
an ongoing clinical
trial,” Dr. Konduri
said.
Green Fluorescence
Red Fluorescence
She is currently
Protein - GBM Cells
Protein - GBM Cells
working with other
researchers at Aurora
in generating a database to determine what types of patients may be eligible
and most appropriate for this type of therapy. Principal biostatistician,
Maharaj Singh, PhD, is aiding with statistical analysis.

“Her passion for finding alternatives to current therapeutic options is evident
in everything she does in the lab,” said senior research technologist Deb
Donohoe, who has worked with Dr. Konduri for almost two years. “Dr. Konduri
is committed to improving the future of cancer treatments at Aurora.”
Dmitry Bosenko, Deb Donohoe and Santhi Konduri
(left to right) work with neuro-oncologist George Bobustuc,
who helps to develop ideas for clinically relevant projects
and presentations.
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PATIENT STORY:
Valerie Johnson
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What started as a headache led to
a trip from Texas to Wisconsin
for the latest in brain surgery.
A DESTINATION FOR CARE
As a figure competitor, Valerie Johnson was in peak
physical condition, but severe headaches caused
her to take a break from training. After many tests,
the 36-year-old Austin, Texas resident learned she
was suffering from a life-threatening brain bleed.
Johnson’s local doctor referred her to the Aurora Neuroscience Innovation
Institute (ANII) team at Aurora St. Luke’s Medical Center because of the
leading-edge image-guided surgical techniques used there.
ANII researchers have been studying the combination of diffusion tensor
imaging (DTI) and functional magnetic resonance imaging (fMRI) to avoid
detrimental consequences in minimally invasive brain surgery like the one
Johnson needed to control the brain bleed. This advanced imaging allows
surgeons to access areas of the brain that control function while		
minimizing complication rates.

Prior to the operation, anesthesiologists deliver a specific dose of
medicine so the patient is aware of what it is going on, but cannot
feel pain.

“The neurosciences team at Aurora was great. They made me
feel at ease with the surgery,” Johnson said. “They assured me that
being awake would be a great benefit to make sure they didn’t do
something that was detrimental to me.”
At one point during the surgery Johnson appeared to be losing motor
skills and she forgot who she was. At this point the doctors raised their
voices to be sure Johnson could hear and respond.
“I was really sleepy from what I recall so in order to keep me awake they
had to talk loudly,” Johnson said.
The team used the 3D map for information regarding the safest way to
proceed to preserve memory and motor function. Not long after making
adjustments, Johnson’s memory returned and she asked to call her mom.

“I could not have done Valerie’s surgery two years ago. That’s how recent
this revolutionary technology is,” said Amin Kassam, MD, vice president of
neurosciences at Aurora Health Care and founder of ANII.

“I do not remember most of it,” Johnson said. “I remember going to
questions on an iPad and talking on the phone with my parents. Even
still, all of that is pretty hazy.”

No sleeping on the job

Back to life

Neuroradiologists designed a three-dimensional map of Johnson’s brain to
plan the safest route for surgeons to take during surgery.

After the surgery, Johnson could speak coherently and answer		
questions, and her motor skills were back to normal.

Johnson’s bleed was located deep in the left side of her brain, surrounded
by areas that control motor and memory function. At Aurora St. Luke’s, the
surgery to control a bleed like that is performed while the patient is awake,
a strategy used at only a handful of hospitals throughout the United States.

The next day, she left the hospital to have lunch with her family and,
a month later, she is already planning to get back into shape. She wants
to start a business of her own someday, but mostly plans to spend more
time with her family in the years to come.

“I could not have done Valerie’s surgery two years ago.
That’s how recent this revolutionary technology is,”
- Amin Kassam, MD
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Neurosciences volumes
Source: Aurora Smart Chart and Medipac

(systemwide)

2014

2015

2016

3,210
2,433
1,510
552
371
387

4,317
1,645
1,094
304
247
446

3,991
1,961
1,426
284
251
357

CASES
Epilepsy
Stroke
Ischemic
Transient ischemic attack
Hemorrhagic
Interventional radiology*
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*Number of patients
(For cancers of the brain and central nervous
system, see table on page 44.)

Neurosciences publications
2016 AURORA-AUTHORED, PEER-REVIEWED
Journal articles/Book chapters
Binder ZA, Wilson KM, Salmasi V, Orr BA, Eberhart CG, Siu IM, Lim M, Weingart JD,
Quinones-Hinojosa A, Bettegowda C, Kassam AB, Olivi A, Brem H, Riggins GJ, Gallia GL.
Establishment and biological characterization of a panel of glioblastoma multiforme (GBM)
and GBM variant oncosphere cell lines. PLoS One 2016;11:e0150271.
Chakravarthi SS, Zbacnik A, Jennings J, Fukui MB, Kojis N, Rovin
RA, Kassam AB. White matter tract recovery following medial
temporal lobectomy and selective amygdalohippocampectomy
for tumor resection via a ROVOT-m port-guided technique: a case
report and review of literature. Interdiscip Neurosurg 2016;6:55-61.
Ditzel Filho LF, Prevedello DM, Jamshidi AO, Dolci RL, Kerr EE,
Campbell R, Otto BA, Carrau RL, Kassam A. Endoscopic endonasal
approach for removal of tuberculum sellae meningiomas. Neurosurg Clin N Am 2015;26:349-61.
Elghouche AN, Lobo BC, Wannemuehler TJ, Johnson KE, Matt BH,
Woodward-Hagg HK, Kokoska MS. Lean Belt Certification: pathway
for student, resident, and faculty development and scholarship.
Otolaryngol Head Neck Surg 2016;154:785-8.
Eliyas JK, Glynn R, Kulwin CG, Rovin R, Young R, Alzate J, Pradilla
G, Shah MV, Kassam A, Ciric I, Bailes J. Minimally invasive transsulcal resection of intraventricular and periventricular lesions through a tubular retractor system: multicentric experience
and results. World Neurosurg 2016;90:556-64.
Johnson-Obaseki S, Kelly K, Corsten M. Response to: “No evidence for improved TORS
post-treatment feeding tube dependency rate relative to standard therapy in early stage
oropharyngeal cancer.” Oral Oncol 2015;51:e68.
Kassam A, Corsten M, Rovin R. The expanded endonasal approach to skull base meningiomas. In: Cappabianca P, Cavallo LM, de Divitiis O, Esposito F (eds). Midline Skull Base Surgery.
Cham, Switzerland: Springer International Publishing, 2016, pp. 215-21.
Krishnamurthy KB, Morris GL III. Folic acid supplementation. In: Sazgar M, Harden CL (eds).
Controversies in Caring For Women With Epilepsy: Sorting Through the Evidence. Cham,
Switzerland: Springer International Publishing, 2016, pp. 39-44.
Labib MA, Shah M, Kassam AB, Young R, Zucker L, Maioriello A, Britz G, Agbi C, Day JD, Gallia
G, Kerr R, Pradilla G, Rovin R, Kulwin C, Bailes J. The safety and feasibility of image-guided
BrainPath-mediated transsulcul hematoma evacuation: a multicenter study. Neurosurgery
2017;80:515-24 [Epub 2016 Jun 17].
Zhang W, Wang ML, Khalili S, Cranford SW. Materiomics for oral disease diagnostics and
personal health monitoring: designer biomaterials for the next generation biomarkers. OMICS
2016;20:12-29.
Abstracts
Ali SI, Mallas-Serdynski L, Thomas K. Get With The Guidelines award winning hospitals
are associated with decreased door to needle times in Michigan and Wisconsin. Stroke
2016;47:ATP294.

dehydrogenase. 2016 Congress of Neurological Surgeons Annual Meeting. Available at:
http://2016.cns.org/posterbrowser.aspx.
Doers T, Chakravarthi SS, Walia S, Rolfs L, Rovin RA, Kassam AB. Initial experience with a
robotics guided optics platform in lumbar spine surgery. 2016 Congress of Neurological Surgeons Annual Meeting. Available at: http://2016.cns.org/posterbrowser.aspx.
Kassam AB, Chakravarthi SS, Celix J, Fukui M, Jennings J, Walia S, Rovin RA.
Initial experience with an image-guided robotically positioned optical platform for aneurysm surgery. Neurosurgery 2016;63 Suppl 1:147-8.
Kassam AB, Chakravarthi SS, Celix J, Khalili S, Corsten M, Walia S, Jennings
J, Fukui M, Rovin RA. Initial experience with an image-guided robotically
positioned optical platform for skull base surgery. 2016 Congress of Neurological Surgeons Annual Meeting. Available at: http://2016.cns.org/posterbrowser.aspx.
Kassam A, Coley D. TMOD-06: Adaptive culture techniques for high grade
glioma, meningioma and brain metastasis. Neuro Oncol 2016;18(suppl_6):vi208.
Kassam AB, Corsten MJ. Reconstruction following EEA: a 0.5% CSF leak rate
in 200 consecutive cases. J Neurol Surg B 2016;77:A136.
Kassam A, Corsten MJ, Curaudeau G, Fukui MB, Rovin R. First in human application of a novel integrated image guided robotic optical telescopic microscopy positioning system: cerebrovascular surgical applications. J Neurol Surg B 2016;77:A131.
Kassam A, Fukui MB, Corsten MJ, Rovin RA, Jennings J. The role of diffusion tensor imaging
in skull base surgery. J Neurol Surg B 2016;77:A128.
Kassam A, Konduri S. ACTR-14: Disulfiram sensitizes glioblastoma to abraxane and temozolomide treatment through inhibition of MGMT and aldehyde dehydrogenase. Neuro Oncol
2016;18(suppl_6):vi4.
Kassam A, Lacrosse A. TMOD-10: Murine avatars permit study of glioblastoma genesis and
progression. Neuro Oncol 2016;18(suppl_6):vi208-9.
Kassam A, Lacrosse A. TMOD-12: A novel patient-derived xenograft model of brain metastasis. Neuro Oncol 2016;18(suppl_6):vi209.
Kassam A, Rovin R. EXTH-10: A novel small molecule therapy sensitizes high-grade glioma to
temozolomide chemotherapy. Neuro Oncol 2016;18(suppl_6):vi61-2.
Labib M, Britz G, Young R, Zucker L, Shah M, Kulwin CG, Maioriello A, Day JD, Gallia G, Kerr R,
Rovin R, Kassam A. The safety and efficacy of image-guided tran-sulcal radial corridors for
hematoma evacuation: a multicenter study. 2015 International Stroke Conference Late-Breaking Oral Abstracts. Available at: http://my.americanheart.org/idc/groups/ahamah-public/@
wcm/@sop/@scon/documents/downloadable/ucm_471665.pdf.
Mintz P, Cucciare M, Coley D, LaCrosse A, Rovin RA, Kassam AB, Kwon CH. Murine avatars
permit study of glioblastoma genesis and progression. 2016 Congress of Neurological
Surgeons Annual Meeting. Available at: http://2016.cns.org/posterbrowser.aspx.

Bobustuc GC, Donohoe DL, Rovin RA, Kassam AB, Konduri SD. Disulfiram sensitizes glioblastoma to abraxane and temozolomide treatment through inhibition of MGMT and aldehyde

87

Together, we have the power to transform care
and create a stronger community.
Gifts to the Aurora Health Care Foundation impact countless
lives and help more people in our community live well. These
donations enhance programs and services that directly affect
people and communities served by Aurora Health Care.
With gifts to Aurora Health Care Foundation, people are helping
our exceptional physicians and caregivers:
Quality health care is people powered.
Thanks to you, our caregivers are able to
continually advance their skills, knowledge and expertise.

LEAD

INNOVATE

Your gift helps expand investments in new
technologies, create better ways to deliver

care and make discoveries that bring the latest in medicine to the
forefront of our practices.

THRIVE

You help provide the latest resources that
empower the people we serve, so that

every person has the opportunity to live well—before and after
receiving care.
Together, we create a stronger
community where access to quality health
care is attainable, especially for those who need it most.

ENGAGE
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We are grateful to our more than 19,000 Foundation

donors who share a commitment to strengthen our communities 			
by supporting Aurora Health Care services and programs. Gifts come in many
forms, some of which include our Grateful Patient Program, Infinity Society,
Planned Giving and Honor or Memorial gifts.
Aurora Health Care is committed to making sure that all patients, regardless
of income, have access to the best care possible. That includes health care
for the un- and underinsured, services for survivors of sexual and domestic
violence, substance abuse treatment and other supportive services for some
of the most vulnerable people in our community. Donors to Aurora have the
ability to have a major impact on these same issues through the programs
Aurora provides, spanning the organization’s service area and serving tens of
thousands of people each year.
Donor support also helps Aurora access the latest technologies and research
to improve patient outcomes and enhance the quality of care we provide.
Your gifts help to advance clinical trials, foster investigator-initiated research
and promote medical education and awareness through publications that
reach more than 100 countries all over the world.

Your gifts help to advance clinical trials,
investigator-initiated research and promote
medical education and awareness reaching
more than 100 countries all over the world.

Your contributions support

cutting-edge research and
helps to develop new therapies
to treat and cure the most
complex and life-threatening
neurological diseases.

Your gifts transform care
in our communities; you
help make hope possible.
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